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5SUMMARY
Angiogenesis is the process by which blood microvessels are formed from existing
ones. Angiogenesis is required for development. It is also important for reducing
myocardial hypoxia due to coronary and ischemic heart disease; in myocardial
infarction or chronic ischemic heart disease angiogenesis responds to tissue hypoxia
by new vessel formation (angiogenesis), which diminishes myocardial ischemia.
However, physiological angiogenesis is usually insufficient to re-establish an
adequate blood supply to the myocardium, which decreases its proper functioning.
Therapeutic angiogenesis in the heart aims at increasing new vessel formation in
ischemic myocardium and thus improving myocardial function by increasing blood
flow (oxygen and nutrient supply). This may contribute to preventing heart failure
and sudden cardiac death. Unfortunately no assay is available to investigate questions
around angiogenesis in an easy format and in a way that does not use big numbers of
animals.
Angiogenesis and hypertension are intrinsically linked; angiogenesis is impaired in
hypertension, and microvascular rarefaction is a mainstay of hypertension-induced
target organ damage. Many metabolic pathways, for example the Renin-Angiotensin-
Aldosterone-System (RAAS) or Nitric Oxide (NO), are involved in the development
of hypertension, hypertension-induced target organ damage and also angiogenesis.
Contrariwise, treatment of hypertension by drugs such as ACE-inhibitors not only
reduces blood pressure and hypertension-induced target organ damage but also
improves angiogenesis and thus tissue oxygenation. Specifically, accumulation of
Bradykinin in response to ACE inhibition may result in angiogenesis. A study in our
laboratory lead us to conclude that impaired angiogenesis in hypertension may result
from impaired NO biosynthesis and not from elevated blood pressure itself. In
addition, activation or RAAS or other factors may affect angiogenesis in
hypertension.
The general aim of this thesis was to first contribute at developing a new angiogenesis
assay of the heart in vitro and to then use it to investigate the role of Angiotensin II
and Nitric Oxide on angiogenesis in the heart in vitro, independent of blood pressure.
We also aimed at understanding mechanisms involved in these responses.
6In order to further study questions of angiogenesis and hypertension in a relevant
target organ, we developed and validated a new in vitro assay for investigating
angiogenesis of the heart. At the time most experiments were being performed in vivo
since no appropriate in vitro model was available. In vivo experiments require a large
number of animals, are difficult to perform and are often associated with pain to the
animals and their death. Our new in vitro model solved or reduced some of these
problems. We found that both hypoxia and serum (5%) are required for angiogenesis
to occur in the adult mouse heart in vitro. We analyzed the morphology of the
different sprouts and found they were always composed by endothelial cells, and that
smooth muscle cells or pericytes align along the sprouts. We conclude that
angiogenesis of the heart in vitro can be investigated with a simple assay that allows a
large series of experiments to be carried out in a relatively short time and with a
minimum number of animals. We have shown that our model is suitable to investigate
the actions of different substances on angiogenesis of the heart, i.e., both substances
that induce angiogenesis and those that may inhibit it.
Subsequently we used our newly developed assay to investigate the role of iNOS on
angiogenesis of the mouse heart and aortae under hypoxia. We found that the heart is
more sensitive to the different inhibitors than aortae. In vitro angiogenesis of the heart
in iNOS knock out mice, in hypoxia, was totally absent. We therefore concluded that
organ specific pathways must exist for angiogenesis; and that for angiogenesis of the
mouse heart, in hypoxia, iNOS is essential.
In the last part of the thesis we describe the work done to understand the role of
Angiotensin II in the hypoxic mouse heart. By using different pharmacological
agonists and antagonists as well as knock out animals we were able to conclude that
the AT2 receptor is the one responsible for angiogenesis in response to Angiotensin II
in the healthy and hypoxic mouse heart in our in vitro model. Further experiments led
us to conclude that the angiogenic effect of Angiotensin II via the AT2 receptor in the
hypoxic mouse heart is mediated via a mechanism that involves the Bradykinin
receptor 2.
In conclusion we have developed a new in vitro model of angiogenesis in vitro of the
heart. Using this model we have analyzed angiogenesis of the hypoxic mouse heart
and then characterized effects of Ang II and NO on angiogenesis in vitro.
71. INTRODUCTION
1.1 Angiogenesis
1.1.1 Introduction
Angiogenesis is the process by which blood microvessels are formed from existing
ones. Angiogenesis is a common process occurring during development as well as
during ischemic heart disease and tumor growth [1, 2]. A capillary is formed by the
tunica intima, which typically only consists of the endothelium, its basal lamina and
an incomplete layer of cells surrounding the capillary, the pericytes. Pericytes, serve
to stabilize the forming capillary tube, have contractile properties and can regulate
blood flow in capillaries [3]. Angiogenesis involves a series of steps that can be seen
represented in figure 1. First, blood vessels dilate and pericytes detach allowing
endothelial cells (EC) to migrate into the perivascular space following angiogenic
stimuli; they will then adhere to each other and create a lumen and finally these new
vessels will fuse with others creating new circulation [4]. Each of these steps is highly
regulated and controlled by a variety of mechanisms and molecules.
Figure 1: New blood vessel formation (a) Blood vessels arise from pre-existing capillaries or
post-capillary venules. (b) First, pericytes (green) detach and blood vessels dilate before the
basement membrane and cellular matrix are degraded. (c) This allows endothelial cells (red)
to migrate into the perivascular space towards angiogenic stimuli. (d) Endothelial cells
proliferate, loosely following each other, and presumably guided by pericytes and
extracellular matrix. (e) Behind the migration columns, endothelial cells adhere to each other
and create a lumen, which is accompanied by basement-membrane formation and pericyte
attachment. Finally, blood-vessels sprouts will fuse with other sprouts to build new
circulatory systems. Little is known about the fusion mechanism. Figure by Bergers.2003. [4].
81.1.2 Angiogenesis of the heart
In diseased hearts such as those that suffer from myocardial infarction or ischemic
heart disease, angiogenesis is a very important process.  In these conditions the blood
vessels supplying blood to the heart muscle narrow or harden, reducing the supply of
oxygen and nutrients to the heart musculature, which is essential for it’s proper
functioning. This may eventually result in a portion of the heart being suddenly
deprived of its blood supply (ischemia) leading to the death of that area of heart
tissue, resulting in a heart attack (myocardial infarction). An improvement in
collateral circulation and thus of blood flow helps enhance the function of diseased
hearts by delivering oxygen and nutrients to areas where needed. Two important
stimuli in these conditions are inflammation and hypoxia [5]. Inflammation and
presence of inflammatory cells is known to be sufficient to induce the formation of
new microvessels [6-8]. Hypoxic areas of the heart lead to the release of angiogenic
growth factors and nitric oxide (NO) [9]. Both hypoxia and myocardial ischemia
upregulate the expression of angiogenic factors [10]. This naturally occurring
angiogenesis is not enough to fully compensate for the loss of oxygen in ischemic
heart conditions, in consequence new ways to increase blood supply are being
investigated by potentation of physiological angiogenesis.
1.1.3 Therapeutic Angiogenesis
Therapeutic angiogenesis involves the development of collateral blood vessels
supplying ischemic tissues, either endogenously or in response to administered
growth factors to improve circulation in affected areas. Clinical trials have been
conducted with administration of growth factors to the human heart [11-14]. Most
studies have focused on the use of known angiogenic factors such as Fibroblast
Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF). Different
methods have been tried to deliver the angiogenic molecules as a natural protein or by
gene transfer but to date no optimal method has been found [10, 15-17]. Therefore the
search continues for the best way to induce therapeutic angiogenesis. Currently,
treatment using stem cells is being tested; this therapy may be the preferred
therapeutic choice because of its clinical applicability and regenerative capacity.
Different types of stem cells such as those leading to the generation of, bone marrow
cells, skeletal and smooth muscle cells, vascular endothelial cells, mesothelial cells,
adipose tissue stroma cells, dental stem cells, and embryonic and fetal cells, have
9been proposed for regenerative medicine. To date ethical as well as immunological
and technical reasons make their clinical use limited [18].
1.2 Hypoxia and the Hypoxic Heart
1.2.1 Defining Hypoxia
The air we breathe contains 21% oxygen and cells in our body are exposed to an
oxygen concentration ranging form 0.5% to 12% depending of the tissue and organ.
In circulating arterial blood oxygen concentration is about 14% and less than 10% in
the myocardium [19]. These variations make it difficult to define hypoxia. A practical
definition is that hypoxia designs any state in which oxygen delivery does not meet
the demand of an organ, tissue or cell [20]. In the myocardium oxygen concentrations
between 0.5-3% are described as hypoxia [19]. For experimental cell culture, hypoxia
is defined as 0.5-3% oxygen concentration. At this level toxicity and growth-
inhibition of cells is not present, and cellular responses to hypoxia can be triggered
[20, 21]. Therefore, we used oxygen concentrations within this range.
1.2.2 The Hypoxic Heart
When a mayor coronary artery is occluded or when deficient growth of the
microvasculature cannot keep up with the rate of the hypertrophying myocardium, the
myocardium becomes ischemic and the heart is said to be hypoxic [22]. At this stage
the vascular supply cannot keep up with the metabolic demands of the heart and this
leads to a state of hypoxia [23]. If the oxygen supply is permanently blocked this can
lead to myocardial infarction.
Hypoxia will stimulate proliferation of both smooth muscle cells (SMC) and
endothelial cells (EC) favouring the creation of new vessels to restore oxygenation.
Hypoxia upregulates various important genes and signalling pathways that have to do
with these processes [21, 24]. Hypoxia-induced genes are controlled by transcription
factor Hypoxia Inducible Factor 1 (HIF-1). HIF-1 activates genes responsible for
angiogenesis such as VEGF [25], nitric oxide synthases [26] and many more. Under
normal oxygen conditions HIF-1 is rapidly degraded. Under hypoxia HIF-1 is
stabilized by inhibition of a prolyl hydroxylase, thus preventing HIF’s proteolitic
degradation.
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1.3 Angiotensin II and Bradykinin
1.3.1 The Discovery of Angiotensin II
Around 1958 two groups of investigators came to the conclusion that ischemia-linked
hypertension they were observing was produced by an enzymatic chain of events
involving renin, in which a pressor substance is generated. The group of Braun-
Menendez, in Argentina, named it ‘hypertensina’ [27] and the group of Page, in the
USA, called it ‘angiotonin’ [28]. By collective agreement the hybrid name
Angiotensin was defined. Angiotensin II (Ang II) is an octapeptide that is generated
by the cleavage from angiotensinogen through the action of two different peptidases
(Angiotensin Converting Enzyme (ACE) and renin). Ang II exerts a wide range of
physiological actions on the cardiovascular, renal and endocrine systems. Its main
action is the regulation of blood pressure and the maintenance of fluid homeostasis
through the renin- angiotensin-aldosteron system (RAAS) [29].
Ang II has a variety of effects on the body; it is a potent vasoconstrictor throughout
the body. In the kidneys, it constricts glomerular arterioles, this increases arteriolar
resistance, raising systemic arterial blood pressure and decreasing the blood flow.
However, the kidneys must continue to filter enough blood despite this drop in blood
flow. To keep glomerular blood pressure up Ang II also constricts efferent arterioles,
which forces blood to build up in the glomerulus, increasing glomerular pressure. The
glomerular filtration rate is thus maintained, and blood filtration can continue despite
lowered overall kidney blood flow. However, increased glomerular filtration pressure
damages the glomerulus with time. Ang II also acts on the adrenal cortex causing the
release of aldosterone, which acts on the tubules (i.e., the distal convoluted tubules
and the cortical collecting ducts) in the kidneys, causing them to reabsorb more
sodium and therefore water from the urine. This also increases blood pressure due to
an increase in intravascular volume. Aldosterone also acts on the central nervous
system to increase a person's appetite for salt, and to make them feel thirsty. These
effects directly act to increase the amount of fluid in the blood, making up for a
potential loss in volume and/or to increase blood pressure [29].
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1.3.2 Synthesis of Angiotensin II
Ang II is synthesised by a cascade of enzymatic reactions [30] as depicted in figure 2.
In the first step, angiotensinogen is cleaved by renin to form Angiotensin I (Ang I),
which is biologically inactive. The Angiotensin Converting Enzyme (ACE) then
converts Ang I into the active octapeptide Ang II by removing 2 amino acids.  The
sequence of Ang II in mammals is Asp-Arg-Val-Tyr-Ile-His-Pro-Phe. Ang II is then
further metabolized to form Ang III and Ang IV which in turn are further metabolized
into small amino acid fragments [31, 32].
Figure 2: Outline of the renin-angiotensin system. ACE: angiotensin converting enzyme. Of
the several alternate pathways of metabolism, the bold, plain and dashed arrows indicate
pathways of decreasing contribution, although minor pathways can always assume major
importance when the main pathway is inhibited. Figure by DJ Campbel, 2003 [33].
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1.33 Angiotensin II Receptors
Ang II exerts its actions by binding to one of its two major receptors, AT1 or AT2.
AT1 Receptor
The AT1 receptor is responsible for most of the known physiological actions of Ang
II in the peripheral tissue and brain [34]. AT1 receptor was successfully cloned in
1991, in humans it’s localized on chromosome 3 and contains 359 amino acids [35,
36]. This sequence is 95% identical to that of rat and bovine AT1 receptors [37, 38].
In rats AT1a and AT1b receptors subtypes exist. They are highly homologous, 95% in
regard to amino acid sequence and 92% in regard to nucleic acids [34].  The AT1
receptor is a seven transmembrane domain receptor and belongs to the family of G-
protein-coupled receptors (GPCR).
AT1 receptors are expressed in all tissues where Ang II is known to exert its classical
effects, in vascular smooth muscle cells (VSMC), uterus, kidneys, heart, lung, urinary
tract and lungs [39-44].  The expression and quantity of AT1 receptors varies among
these different tissues. The pattern of distribution suggests that this receptor exerts
very important biological functions in these tissues; distribution of expression can be
affected by various pathological conditions such as hypertension and myocardial
infarction [45-47].
The signalling mechanisms of this receptor have been extensively studied. As a
member of the G-Protein Coupled Receptor (GPCR) family it seems to couple mainly
to Gq activating a cascade that involves Phospholipase C (PLC) leading to the
formation of inositol triphosphate (IP3) and diacylglycerol (DAG). These second
messengers are then responsible for several of the effects regulated by the AT1
receptors such as vascular smooth contraction and secretion of aldosterone [34]. Other
signalling pathways also exist and are represented in figure 3.
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Figure 3: Signal transduction mechanisms and physiological effects mediated by AT1
receptor. Figure by DT Dinh et al 2001 [48]
Deletion of the gene encoding the AT1A receptor subtype in mice significantly
reduces blood pressure and pressor responses to infused Ang II [49, 50]. Conversely,
in AT1B receptor knock-out mice, systemic blood pressure is normal, suggesting that
the AT1A receptor is the major receptor involved in blood pressure regulation [51].
However, exogenous Ang II infusion can still elicit pressor effects in AT1A deficient
mice, which can be blocked by AT1 receptor antagonists [52]. Although these pressor
responses were smaller than those seen in wild-type mice, it still suggests a role for
the AT1B receptor in blood pressure regulation, particularly in the absence of
functional AT1A receptors. Recently, transgenic mice over-expressing the AT1
receptor in cardiac myocytes have been shown to develop cardiac hypertrophy and
remodelling, with no change in blood pressure, and died prematurely of heart failure
[43]. This suggests that Ang II, via activation of AT1 receptors, is directly involved in
the development of cardiac hypertrophy and heart failure, independently of blood
pressure. In 1998 AT1A/AT1B mice were generated by Oliverio et al [53]. These
mice present diminished growth, vascular thickening of the kidney and atrophy of the
inner renal medulla [53]. These mice have no systemic pressor response to infusions
of Ang II, and have reduced blood pressure [53]. Taken together all their results point
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to the important of AT1 receptors in mediating the physiological functions of the
RAAS.
AT2 Receptor
The AT2 receptor has been cloned in mouse, rat and humans [54-58] in all species it
resides as a single copy on the X-chromosome [59]. The cDNA encodes for a receptor
with 363 amino acids, with high homology on the nucleic acid (89%) and amino acid
levels (91%) between rodent and humans. Comparison with the AT1 receptor yields a
very poor homology, of just 34%.
AT2 receptors are predominantly expressed in fetal tissues. After birth the ratio of
AT1 to AT2 receptors is reversed, with the AT1 being the dominant one in most
tissues of the adult organism [60]. In the adult both receptors can be found in the
adrenal gland, vascular endothelial cells, kidneys and heart, whereas the AT2 receptor
predominates in the uterus, ovarian granulosa cells and some brain areas [60-62].
Even though the AT2 receptor is not commonly expressed in adult tissues it can
dramatically increase under pathological conditions such as vascular injury,
congestive heart failure, renal failure, brain ischemia and myocardial infarction [60].
This expression patterns can be influenced by a variety of growth factors and
hormones in different tissues [63].
The signalling pathway of the AT2 receptor has turned out to be quite complex, even
though the AT2 receptor has the structural features of a seven transmembrane
receptor, it does not reveal the shared functional features of this family of receptors.
The pathways that have been so far described seem to depend on tissues or cells as
well as on the experimental conditions. Some of the known pathways are described in
figure 4. One important pathway is the activation of guanylate cyclase leading to
increased levels of cGMP, NO production and its release [64-66].
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Figure 4: Signal transduction mechanisms and physiological effects mediated by AT2
receptor. Figure by DT Dinh et al 2001 [48]
In contrast to AT1 receptor gene deletion, targeted deletion of the AT2 receptor gene
in mice results in animals that develop normally, but have an impaired drinking
response to water deprivation as well as a reduction in spontaneous movements. Their
baseline blood pressure is normal, but they show an increased vasopressor response to
injection of Ang II, [67, 68]. This suggests that the AT2 receptor mediates a
vasodilation effect and may functionally oppose the effects mediated by the AT1
receptor, possibly via bradykinin and NO [69].
Given that AT2 receptors are highly abundant in fetal tissues, such as the heart,
kidney and brain, and disappear soon after birth, they were believed to play an
important role in foetal development. However, AT2 receptor knockout mice
apparently develop and grow normally and do not show observable morphological
defects, suggesting that the AT2 receptor may not be essential for fetal development
[67, 68]. AT2 receptor knockout mice also show impaired drinking responses to water
deprivation and reduced exploratory behaviour [67, 68].
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1.3.4 Agonists and Antagonists of the Angiotensin II Receptors
Selective AT1 antagonists abound, they all belong to the family of so called ‘sartan’
compounds and are currently used to effectively treat hypertension [60]. In this work
we have used Losartan as an AT1 inhibitor. A selective AT2 antagonist is PD 123319,
which binds with high affinity to this receptor.  An agonist for AT2 receptor is also
being currently used in research, CGP 42112; no specific AT1 receptor agonist has
been described to date.
1.3.5 The Kallikrein-Kinin System and Bradykinin
Bradykinin (BK) belongs to the family of kinins, molecules that participate in
inflammatory processes by activating endothelial cells. They also lead to vasodilation,
increased vascular permeability and NO production [70, 71].  BK is liberated by
plasma kallikrein from high molecular weight kininogen (see figure 5) and acts as a
potent short-lived vasodilator.
The BK receptors, BKR1 and BKR2, belong to the family of GPCRs. BKR2 is
predominant in most tissues and constitutively expressed [72] and is the one
responsible for most of the known biological effects.
The Bradykinin receptor 2 knock-out mouse is a very good model to study the
interaction of BK and Ang II. These mice develop mild hypertension, cardiac
hypertrophy, chamber dilation and myocardial damage. They have elevated left
ventricular and end-diastolic pressure, and show exaggerated vasopressor response to
Ang II. In the presence of Ang II they have increased blood pressure and reduced
renal blood flow [73, 74].
1.3.6 The interaction between the plasma Kallikrein-Kinin system and the Renin
Angiotensin system.
The plasma kallikrein-kinin system (KKS) has been traditionally linked to
physiological homeostasis. In recent years the link between BK and NO production
and NO mediated pathological effects has been increasingly studied [75]. The
endothelial cell-associated active kallikrein cleaves the higher molecular weight
kininogen to form BK, which in turn regulates vascular tone by stimulating NO
production in endothelial cells via BKR2 [76].
ACE and prolycarboxypeptidase (PRCP), are key molecules linking both systems, as
can be seen in figure 5. ACE is responsible for converting Ang I to the
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vasoconstrictor Ang II but it also degrades BK into smaller peptides. PRCP degrades
Ang II into Ang(1-7) which, causes vasodilation and stimulates NO and prostaglandin
formation. This potentiates the effects of BK. PRCP can also convert prekallikrein
into kallikrein that then cleaves kininogen to liberate BK. The KKS is activated by
various stimuli such as tissue damage, ischemia and inflammation [77].
Figure 5: The interaction between the plasma KKS and RAS. Plasma kallikrein converts
prorenin to renin, and renin has the ability to convert angiotensinogen to angiotensin I.
Angiotensin-converting enzyme (ACE) converts inactive angiotensin I to the vasoconstrictor
angiotensin II. Angiotensin II stimulates plasminogen activator inhibitor 1 (PAI1) release
from endothelial cells. At the same time ACE degrades bradykinin into bradykinin (1–7) (not
shown) or bradykinin (1–5), a peptide with thrombin inhibitory activity. PRCP is the enzyme
that degrades angiotensin II or angiotensin I to the vasodilating peptide, angiotensin II (1–7).
Angiotensin II (1–7) stimulates NO and PGI 2formation, which potentiates the effects of
bradykinin. PRCP also has the ability to convert PK to kallikrein. Formed kallikrein digests
kininogens to liberate bradykinin, leaving a kinin-free kininogen (HKa) that has anti-
proliferative and anti-angiogenic properties. Thus, PRCP, the same enzyme that degrades the
vasoconstrictor angiotensin II, leads to the increased formation of the vasodilators bradykinin
and angiotensin II (1–7). Finally, the resulting bradykinin stimulates TPA, NO, and PGI 2
formation, thus counterbalancing the prothrombotic effect of angiotensin II. Figure by
Schmaier, 2002. [76]
1.4 Nitric Oxide
1.4.1  Introduction to Nitric Oxide
Nitric Oxide is a gas and a free radical first described in the 1980s as an endothelium-
derived relaxant of vascular smooth muscle cells [78, 79]. NO relaxes the smooth
muscle in the walls of the arterioles. At each systole, the endothelial cells that line the
blood vessels release NO. This diffuses into the underlying smooth muscle cells
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causing them to relax and thus permit the surge of blood to pass through easily. Since
its discovery NO has been extensively studied, discovering its important role as a
signalling molecule in most biological systems.  Many of its effects are mediated
through the activation of guanylyl cyclase which increases 3’,5’-cyclic guanosine
monophosphate (cGMP) formation from guanosine 5’-triphosphate (GTP) [80-83].
NO is synthesized by a group of enzymes called nitric oxide synthases (NOS) [80-
85]. Three isoforms have been identified, neuronal NOS (nNOS), inducible or
inflammatory NOS (iNOS) and endothelial NOS (eNOS). These forms share
approximately 50% homology of sequence and have nearly identical mechanisms of
action. NOSs catalyze the production of NO and citrulline from L-arginine, oxygen
and NADPH-derived electrons. All these NOSs are found in different cellular
locations and can be induced by different stimuli even if only iNOS is called
inducible NOS [84].
1.4.2 iNOS
In normal healthy quiescent cells iNOS is not expressed [85]. But after induction by
immunologic or inflammatory stimuli iNOS is expressed in a large variety of cells
[85-88]. Cytokines such as interferon-gamma (IFN), tumor necrosis factor (TNF),
interleukin-1 and -2, and lipopolysaccarides (LPS) cause an increase in iNOS mRNA,
protein, and activity levels. Once expressed, iNOS generates large volumes of NO
often reaching detrimental levels [84, 85, 87]. NO is induced in various pathological
conditions such as inflammatory and non-inflammatory pain, asthma, arthritis, septic
shock and in the brain after trauma or ischemia [85, 87]. Newer data point also to
beneficial effects of iNOS induction, as observed in iNOS knockout animals. iNOS is
important in skin wound healing and healing of the intestinal mucosa as well as
required for bone resorption by osteoclasts. Importantly it is also involved in
angiogenesis [85, 87].
1.4.3 Angiogenesis and Nitric Oxide
NO is required for in vivo angiogenesis and for endothelial tube formation in vitro
[89-91].  NO causes vasodilation, a key process that precedes endothelial sprout
formation at the start of the angiogenic process [92, 93]. NO is also involved in
angiogenesis by influencing the activity of various growth factors that are known to
be angiogenic such as VEGF [1, 5, 94]. The importance of NO for angiogenesis has
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also been seen in knockout mice, both eNOS and iNOS knockouts display impaired
angiogenesis in models of capillary in-growth into Matrigel plugs and models of skin
flap survival respectively. [87, 95-97].
NO is also required for the process of wound healing of which angiogenesis is a key
process [98-100]. In tumours it has been shown that NO is essential for growth [93,
101-104].  In a model of arterial hypertension impaired angiogenesis was observed.
This is thought to be brought about by an impaired NO biosynthesis [105]. Exactly
how NO affects angiogenesis is still unclear, most of the signalling mechanisms
remain to be studied [106, 107].
1.5 Hypertension
1.5.1 Arterial Hypertension and microvascular rarefaction
Blood pressure is a measurement of the force applied to the walls of the arteries as the
heart pumps blood through the body. The pressure is determined by the force and
volume of blood pumped and the size and flexibility of the arteries. Blood pressure is
continually changing depending on activity, temperature, diet, emotional state,
posture, physical state, and medication use. Normal blood pressures fall in the range
of 90/60 mm Hg to 130/80 mm Hg. The first of these 2 numbers is the systolic blood
pressure reading, and it represents the maximum pressure exerted when the heart
contracts. The second number is the diastolic blood pressure reading, and it represents
the pressure in the arteries when the heart is at rest [29].
Arterial hypertension is the elevation of blood pressure beyond the normal range.
Persistent hypertension is one of the risk factors for stroke, heart attack and heart
failure as well as of chronic renal failure.  Arterial hypertension is also characterized
by reduced NO biosynthesis, increased vasoconstriction and by microvascular
rarefaction (reduction of microvascular density). Rarefaction has been observed in
animal models of hypertension and also in human patients [108, 109]. Microvascular
rarefaction contributes to increased peripheral resistance and in consequence to the
development of chronic arterial hypertension [108], it also impairs blood flow to
important areas of the heart such as the myocardium [109]. Hypertension causes
damage to target organs, leading to high levels of morbidity and mortality. Untreated
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hypertension can lead to heart diseases such as left ventricular hypertrophy and
myocardial ischemia that may lead to stroke and sudden cardiac death. [110].
1.5.2 Hypertension and the heart
Over time hypertension and its associated risk factors may lead to the development of
left ventricular hypertrophy (LVH) or myocardial infarction as schematically shown
in figure 7. LVH is characterized by rarefaction of microvessels and in consequence
ischemia of the left ventricle. This can lead to systolic and diastolic dysfunction
which can lead to further heart failure.
Figure 7: Progression from hypertension to heart failure. CHF= congestive heart failure;
CV=Cardiovascular; HF= heart failure; LV= left ventricular; LVH= left ventricular
hypertrophy; MI= myocardial infarction. Figure by R. Humar
1.5.3 Anti-Hypertensive Drugs
The goal of antihypertensive therapy is to normalize blood pressure and to prevent
cardiovascular complications of hypertension, such as heart failure, stroke, end stage
renal disease, and death.
Many treatments for hypertension are currently on the market but two of the
antihypertensive drugs relevant to this thesis and most commonly used are ACE
inhibitors and Ang II receptor blockers (ARB). The beneficial effects of ACE
inhibitors are generally attributed to a decrease in the ACE mediated generation of
Ang II and the accumulation of bradykinin [111]. ARB’s act by selectively blocking
the binding of Ang II to the AT1 receptor but not to the AT2 receptor [112-114].
Clinical evidence suggests that this mechanism of action has some benefits that go
beyond blood pressure control. Patients after acute myocardial infarction and patients
with chronic heart failure benefit from treatment with ARB equally compared to
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treatment with ACE inhibitors. Hypertensive patients with electrocardiographically
left ventricular hypertrophy treated with ARB seem to have an additional benefit in
terms of morbidity and mortality compared to treatment with beta-blockers [115]. In
the early stages of stroke, patients treated with ARB have a lower 12-mounth
mortality than patients receiving placebo [116].
1.5.4  Hypertension and Angiogenesis
As mentioned above microvascular rarefaction has been identified in hypertensive
patients and animal models [1, 2]. Late-onset hypertension is associated with a lack of
coronary angiogenesis [117]. Inadequate angiogenesis is closely related to
hypertension per se or hypertension related organ damage [1, 2]. Studies suggest that
the impaired angiogenesis observed may be due to reduced NO biosynthesis,
activation of the RAAS and other factors [105, 118].  Thus, improved angiogenesis
could help relieve the onset of hypertension and prevent organ damage.
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2. RATIONALE AND AIMS
Angiogenesis is a highly regulated process that arises in response to hypoxia and
other stimuli to relieve tissue ischemia.  To study this process most experiments are
performed in vivo, requiring large number of animals. These experiments are often
associated with pain and death of many animals. An appropriate in vitro model would
be desirable to solve some of these problems.
Nitric oxide (NO) is a key signaling molecule and regulator of angiogenesis. NO
produced by inducible NOS (iNOS) modifies both angiogenesis and vascular
permeability. iNOS expression is significantly increased during myocardial ischemia
and infarction. This lead to the idea of studying whether a deficiency of iNOS impairs
myocardial angiogenesis.
Therapeutic angiogenesis is based upon improving myocardial function by increasing
blood flow (oxygen and nutrient supply) to ischemic areas of the heart, thus
preventing heart failure and sudden cardiac death. After renal ischemia Ang II
restores blood flow by stimulating the development of collateral circulation,
independent of its hypertensive effect [1]. This lead to the idea of studying Ang II as a
possible target for therapeutic angiogenesis.
The aim of this study was to investigate the role of Angiotensin II and Nitric Oxide on
angiogenesis in the heart in vitro, independent of blood pressure, using our newly
developed system of angiogenesis in vitro of the heart. We also aimed to understand
the mechanisms involved in these responses.
Our objectives were:
1. To investigate and validate a model of angiogenesis of the heart in vitro
2. To characterize the cells involved in the sprouting
3. To assess the response of the heart to important angiogenic stimuli under
different experimental conditions
4. To study the function of iNOS on angiogenesis of the heart and aorta in vitro
under conditions of hypoxia
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5. To determine the angiogenic effect of Ang II in vitro in normoxia and
hypoxia.
6. To study the receptors involved in the angiogenic response due to Ang II in
hypoxia.
7. To study the involvement of the Bradykinin pathway in the angiogenic
response elicited by Ang II
Reference
[1] Fernandez LA, Caride VJ, Twickler J, Galardy RE. Renin-angiotensin and
development of collateral circulation after renal ischemia. Am J Physiol. 1982;
243: H869-75.
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Abstract
Arterial Hypertension (AH) is characterized by reduced nitric oxide (NO)
biosynthesis, activation of the Renin-Angiotensin-Aldosteron-System (RAAS),
vasoconstriction, and microvascular rarefaction. The latter contributes to target organ
damage, especially in left ventricular hypertrophy, and may partially be due to
impaired angiogenesis.
Angiogenesis, the formation of new microvessels and microvascular networks from
existing ones, is a highly regulated process that arises in response to hypoxia and
other stimuli and that relieves tissue ischemia. In AH, angiogenesis seems impaired.
However, blood pressure alone does not affect angiogenesis, and microvascular
rarefaction is present in normotensive persons with a family history for AH.
Normal or increased NO in several processes and diseases enables or enhances
angiogenesis (e.g. in portal hypertension) and reduced NO biosynthesis (for example,
in a rat model of AH, in other disease models in vivo, and in endothelial NO Synthase
knock out mice) impairs angiogenesis. Angiogenic growth factors such as Vascular
Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF) induce NO
and require NO to elicit an effect. Effector molecules and corresponding receptors of
the RAAS either induce (Bradykinin, Ang II) or perhaps inhibit angiogenesis. The
pattern of Bradykinin- and Angiotensin II-receptor expression and the capacity to
normalize NO biosynthesis may determine whether ACE-inhibitors, Angiotensin II
Receptor antagonists and other substances affect angiogenesis. Reconstitution of a
normally vascularized tissue by reversal of impaired angiogenesis with drugs such as
ACE inhibitors and AT1 receptor antagonists may contribute to successful treatment
of hypertension-associated target organ damage, e.g. left ventricular hypertrophy.
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Introduction
Arterial Hypertension is associated with altered function and structure of big and
small vessels. Abnormal regulation of vasomotor tone, enhanced vasoconstriction,
reduced vasodilation, structural alterations of arteries, microvessels and microvascular
networks substantially contribute to hypertension and hypertension-associated target
organ damage. Structurally, hypertension increases the thickness of artery walls,
increases the wall-to-lumen ratio, and alters the composition of the arteries. In
microvessels, hypertension reduces the numbers of small arteries and capillaries [1,
2]. Specifically, primary hypertension of animals and humans is consistently
associated with microvascular rarefaction [1, 2]. Hypertension can also cause
microvascular rarefaction by two fundamental mechanisms - either destruction of
microvessels because of increased blood pressure or, as recently detected, via
impaired angiogenesis [2, 3]. The link between hypertension and impaired
angiogenesis is the main focus of this review.
The centre of attention in antihypertensive therapy has been to induce vasodilation
[3]. In addition, antihypertensive therapy has increasingly been targeted at target
organ damage including changes of vascular structure and left ventricular
hypothrophy [4]. Attention has recently also been directed at reducing or even
reversing microvascular rarefaction [3]. Interestingly, several antihypertensive drugs,
which were initially designed to promote vasodilation, are now known to improve
altered structure of arteries and microvascular networks. These latter effects require
time whereas changes of vascular tone occur quickly.
To reverse microvascular rarefaction by antihypertensive therapy, microvascular
networks that have been destroyed in response to high blood pressure or that have not
formed because of hypertension-associated impaired angiogenesis need to be
established or reestablished.
Several observations suggest that microvascular rarefaction in hypertension may also
be due to impaired angiogenesis and that this can be reversed: (i) Microvascular
rarefaction precedes manifest elevation of blood pressure and hypertension in persons
with a family history of hypertension and in animal models of hypertension [1]; (ii)
Nitric oxide (NO) biosynthesis and the Renin-Angiotensin-Aldosteron-System
(RAAS) play pivotal roles in the development of hypertension and both regulatory
pathways affect angiogenesis substantially; (iii) Induction of arterial hypertension by
NO-biosynthesis inhibitors leads to impaired generation of a vascularized connective
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tissue in vivo, i.e., impaired angiogenesis; and (iv) Antihypertensive treatment can
reverse microvascular rarefaction in animal models of hypertension in vivo.
In this review we will discuss some basic mechanisms of angiogenesis and their
involvement in hypertension along the four points mentioned above.
Angiogenesis
Formation of new blood vessels involves three fundamentally different processes;
vasculogenesis, angiogenesis, and arteriogenesis.
In vasculogenesis, blood vessels form de novo during embryogenesis.
Undifferentiated precursor cells (angioblasts) differentiate to endothelial cells which
then assemble to primitive vascular networks [5-8].
Angiogenesis refers to the formation of new blood vessels from existing microvessels.
It serves the supply of oxygen, nutrients, and the removal of waste. The key sequence
of events in angiogenesis can be briefly summarized as follows: Capillary blood
vessels consist of endothelial cells and pericytes. These two cell types carry
information to form new tubes, branches, and entire new capillary networks. Several
stimuli such as hypoxia due to insufficient tissue perfusion induce angiogenesis via
release of angiogenic molecules [6-9]. Tissue hypoxia occurs when the vascular
supply is overwhelmed by increasing metabolic demands. For example, hypoxia
emerges in growing tumors, myocardium in coronary heart disease, striated muscles
in peripheral artery disease or in ischemic parts of the retina in diabetic patients.
Tissue hypoxia promotes the release of molecules that induce angiogenesis and a
vascularized connective tissue stroma. These molecules include Vascular Endothelial
Growth Factor (VEGF), Platelet-derived Growth Factor (PDGF), and Fibroblast
Growth Factor (FGF) [10, 11]. Initiation of angiogenesis and the release of
angiogenic molecules induces vasodilation, increased vascular permeability, and
expression of proteolytic enzymes [8]. Release of Nitric Oxide (NO), for example in
response to hypoxia or specific disease states, is important in mediating initial
vasodilation in angiogenesis [8, 12]. NO can also upregulate VEGF leading to
increased vascular permeability and angiogenesis [13]. In addition to NO and VEGF
many other molecules are involved in initiation of angiogenesis (see below) [6, 8, 9].
Next, endothelial cells begin to proliferate and to migrate towards the source of
angiogenic molecules. The basement membrane and subendothelial extracellular
matrix are subsequently degraded. Then endothelial cells reassemble along tracks of
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extracellular matrix [14], form cords and finally tubes after acquiring a lumen [5-8].
Each of these steps is highly regulated by an extensive number of different interacting
intracellular and extracellular molecules and cellular receptors [6, 8, 9]. Thus,
angiogenesis contributes to expansion and remodeling of the vascular network by
proliferation and sprouting of endothelial cells, addition of pericytes, and by splitting
of capillaries [5-8]. Finally, capillary vessels coalesce to a complex vascular network.
Angiogenesis is usually turned on for brief periods (days) and then completely
inhibited. However, in some processes and diseases the balance of angiogenesis is
persistently tipped towards upregulation (cancer, diabetic retinopathy) [7] or
downregulation (arterial hypertension: see below) [15].
During subsequent arteriogenesis some vessels reassemble and develop a
multilayered muscular coat which provides blood vessels with viscoelastic and
vasomotor properties. New arteries form which adapt tissue perfusion to changing
needs [5-8]. Arterogenesis is a process that is both phenomenologically and
mechanistically totally different from angiogenesis [16-18].
Angiogenesis occurs in a broad array of physiologic and pathologic processes [5-7, 9,
19]. For example, angiogenesis is a prerequisite of normal tissue growth,
embryogenesis, wound healing, the ovarial - and menstrual cycle. Furthermore,
angiogenesis promotes cancer growth and metastasis, diabetic retinopathy, and
instability of atherosclerotic plaques [5-7, 9, 19]. On the other hand, angiogenesis is
present but usually insufficient to restore normal left ventricular function in ischemic
myocardium due to coronary heart disease or ischemic skeletal muscle due to
peripheral artery disease [20-22].
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Rarefaction of microvessels in hypertension
Arterial hypertension is characterized by reduced NO biosynthesis, increased
vasoconstriction, and by reduced microvascular density, i.e., rarefaction of arterioles
and capillaries. Microvascular rarefaction is found in animal models of hypertension
and in human hypertensives [1, 2]. Specifically, decreased numbers of small arterioles
have been found in spontaneously hypertensive rats [23, 24], and microvascular
rarefaction has been associated with high salt intake in skeletal muscle of Dahl salt
sensitive rats [25, 26]. Microvascular rarefaction has also been detected in
hypertensive patients [1, 27] and even in offspring of hypertensives [1].
 Microvascular rarefaction contributes to increased peripheral vascular resistance and
in consequence to the development of chronic arterial hypertension [1]. It also impairs
target organ blood flow, for example to the myocardium [2]. Indeed, rarefaction of
intramyocardial vessels is one of the most relevant structural alterations in
hypertension-induced left ventricular dysfunction, hypertrophy, and ischemia [1].
Interestingly, microvascular rarefaction induced by high sodium diet in Sprague-
Dawley-reduced-renal-mass rats can be reversed after return to a low sodium diet
upon normalisation of blood pressure [28].
Elevated blood pressure is well known to destroy microvessels which contributes to
microvascular rarefaction [23, 24]. However, blood pressure-independent
mechanisms can contribute to arteriolar rarefaction in arterial hypertension [1, 29]
Interactions between hypertension and angiogenesis
As mentioned above, offspring of patients with hypertension, that have not yet
developed arterial hypertension themselves, show rarefaction of microvessels [1].
Deficient angiogenesis, i.e., inadequate upkeep and development of a vascularized
connective tissue in target organs, may reduce microvascular density in persons prone
to hypertension [1]. Hypothetically, impaired angiogenesis in patients prone to
hypertension may evolve because of genetic disposition, deficient placental and
embryonal vascular development and thus low birth weight, and also impaired
postembryonic vascular growth in general and in target organs (for example
hypertrophying myocardial tissue). Inadequate formation of new blood vessels, i.e.,
impaired angiogenesis, may thus be intrinsically associated with hypertension and
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development of hypertension-dependent target organ damage [1-3, 7, 9]. However,
this has not been elucidated yet in detail.
Mechanistically, interactions of angiogenesis and hypertension may involve amongst
others blood pressure itself, nitric oxide, angiogenic molecules, and the Renin-
Angiotensin-Aldosteron-System (RAAS). In an own series of experiments we found
that blood pressure itself did not seem to affect the extent of angiogenesis in Dahl salt
sensitive rats “Fig. (1)” [15]. However, decreased NO biosynthesis reduced
angiogenesis in the same study in a rat model of secondary hypertension “Fig. (1)”
[15]. Thus, rather than from elevated blood pressure itself, impaired angiogenesis in
hypertension may result from metabolic changes associated with hypertension such as
impaired NO biosynthesis [15], activation of the RAAS, and other factors [1, 15].
Recently, increased plasma levels of VEGF have been found in hypertensive patients
[30, 31]. Specifically, VEGF and its soluble receptor sFlt-1 in patients with essential
hypertension revealed an elevation of VEGF [30, 31] and a reduction of sFlt-1 levels
[30] compared to normotensive control patients. Treatment of hypertension reduced
plasma levels of VEGF [30, 31] and increased plasma levels of sFlt-1 [30]. Therefore,
antihypertensive therapy seems to normalize deregulated angiogenic markers and
possibly restore the normal potential for angiogenesis.
Interactions of hypertension and angiogenesis may also be present in diabetes.
Diabetes is closely linked to some forms of essential hypertension [32, 33].
Hypertension contributes to diabetic microvascular and macrovascular complications
[33-36]. These complications are often related to aberrant angiogenesis. Excessive
angiogenesis in response to retinal microvascular damage and ischemia plays a role in
diabetic retinopathy, and impaired angiogenesis contributes to diabetic neuropathy,
poor wound healing in diabetic patients, embryonic vasculopathy in pregnancies
complicated by maternal diabetes [37]. VEGF and sFlt-1 levels of diabetic patients in
plasma are modified may be associated with deregulated angiogenesis [38, 39].
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Figure 1: Inhibition of NO biosynthesis but not elevated blood pressure reduces
angiogenesis [15].
Angiogenesis in vivo was investigated in two models of secondary arterial hypertension using
a wound chamber model in vivo [15, 60, 70]. Arterial hypertension was induced by salt
feeding of DSS (dahl salt sensitive) rats and inhibiting Nitric Oxide biosynthesis by Nw-
Nitro-L-Arginine (NNA) in WKY rats [15].
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Panels A - D show blood pressure (A) and morphometric parameters (C-D). Blood pressure
increases significantly in response to salt-feeding and Nitric Oxide biosynthesis inhibition
(con = control rats, 1% salt = salt-feeding with 1% salt in the drinking water, NNA = 150 mg
Nw-Nitro-L-Arginine/ l H2O in the drinking water). The total number of vessels (B), the
surface of ingrown tissue (C), and the vessel area (D) decrease by inhibition of NO
biosynthesis but not by high blood pressure in response to salt feeding [15].
Panel E to H show sections through wound chambers. Panel E shows a cross section of a
wound chamber of a control rat with tissue ingrown into the wound chamber at 20x
magnification. Similar patterns are also observed for salt-fed rats (not shown). Inhibition of
NO biosynthesis massively reduces the surface of ingrown tissue (F). Panel G shows a
vascularized wound chamber at higher magnification (400x), as observed in control groups
and salt-fed rats. Inhibition of NO biosynthesis (Panel H) reduces the total number of blood
vessels and decreases their size [15]. Arrows in G and H point to blood vessels.
Angiogenesis and Nitric Oxide (NO)
Reduced NO bioavailability plays a central role in the development of arterial
hypertension, and NO is required for angiogenesis in vivo and growth-factor-mediated
endothelial tube formation in vitro [40, 41]. NO acts as a mediator in the vascular,
nervous, and immune systems by regulating vascular permeability, vasodilation,
tumor blood flow, platelet adhesion and aggregation, and other functions [42-44]. As
mentioned above, vasodilation precedes sprout-formation at initiation of angiogenesis
[8, 12]. This vasodilation may be NO-mediated, and NO-mediated vasodilation may
be a prerequisite of elongation, migration, and proliferation of endothelial cells,
cellular actions which are all required for angiogenesis (see above) [12].
NO is also involved in regulation of angiogenesis by influencing the activities of
different angiogenic growth factors. Most evidence for the involvement of NO in
angiogenesis has been generated with VEGF, an angiogenic growth factor [6, 7, 9,
45]. VEGF induces NOS and NO biosynthesis which are required for subsequent
angiogenesis [46-50]. Conversely, NO also activates VEGF mRNA and protein
expression [13, 51]. The importance of NO in angiogenesis has also been
demonstrated in knockout mice. Both inducible nitric oxide synthase (iNOS) and
endothelial NOS (eNOS) knockout mice display impaired angiogenesis [52-55].
Recently, iNOS has been found to drive angiogenesis dependent skin flap survival; in
a mouse model in which survival of a skin flap entirely depends on angiogenesis to
41
provide an arterial blood supply, targeted disruption or selective inhibition of the
iNOS gene reduces skin flap survival [53]. In a rat model of ischemic cardiomyopathy
needle-induced transmyocardial revascularization (TMR) iNOS may contribute to the
angiogenic response of TMR [56]. In this model a mechanical injury using needle
puncture leads to increased expression of myocardial iNOS and is associated with
increased vascular density [56]. Furthermore, ACE inhibition and Bradykinin induce
eNOS in ischemic hind limbs of mice [57], in rat endothelial cells [58], and in rabbit
coronary postcapillary venular endothelial cells [59] and thereby elicit angiogenesis
[57-59]. Beside VEGF, other angiogenic growth factors can also require NO. FGF for
example requires NO in mesenterial angiogenesis in vivo; inhibition of NO formation
in an own study diminishes unstimulated and bFGF-stimulated angiogenesis in the
mesenterium of rats [60].
NO is also necessary for wound healing, of which angiogenesis is an integral part [61-
63]. During early stages of wound healing end products of NO synthesis (nitrite,
nitrate) are elevated [64]. Furthermore, nitric oxide synthase (NOS) inhibitors delay
wound healing [65, 66]. Both inducible nitric oxide synthase (iNOS) and endothelial
NOS (eNOS) have directly been implicated in wound healing and are required for
proper endothelial cell migration, proliferation, and differentiation [52, 54]. Tumor
tissues express elevated levels of total NOS, iNOS and cGMP [12, 67, 68], and
inhibition of NO biosynthesis by Nw-nitro-L-arginine-methyl ester (L-NAME)
reduces tumor-induced angiogenesis [12, 67-69].
The essential role of NO for angiogenesis is also supported by data in many other
diseases. However, we next focus on diseases with a relevant hemodynemic aspect.
Portal hypertension is defined as an increased pressure in the portal vein and its
tributaries. However, in the systemic circulation portal hypertension has many
characteristics that are quite the opposite of arterial hypertension. Portal hypertension
leads to elevated NO biosynthesis, systemic vasodilation, and a decrease in blood
pressure. Interestingly, we found portal hypertension to increase NO dependent
angiogenesis in the mesenteric vascular bed of rats [70]. In other words, portal
hypertension leads to increased angiogenesis via NO biosynthesis [70].
In a further series of experiments we found that decreased NO biosynthesis reduced
angiogenesis in a rat model of secondary hypertension “Fig. (1)” [15]. Interestingly,
blood pressure itself did not affect the extent of angiogenesis “Fig. (1 )” [15].
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Therefore, arterial hypertension may be associated with reduced angiogenesis due to
impaired NO biosynthesis [15].
All of these results support a central role for NO in angiogenesis and also arterial
hypertension-associated impairment of angiogenesis. However, the specific cellular
signaling mechanisms by which NO affects angiogenesis are not yet well
characterized. Especially, it is still unclear whether NO acts directly on endothelial
cells or via growth factor dependent effects [71, 72]
Angiogenesis and the Renin-Angiotensin-Aldestoron System
The Renin-Angiotensin-Aldosteron System (RAAS) plays a central role in blood
pressure control. It contributes to the pathophysiology of hypertension and to target
organ damage [73-75]. Target organ damage includes vascular remodeling,
glomerular damage to the kidney, and remodeling and hypertrophy of the left
ventricle (left ventricular hypertrophy) [73-75]. The RAAS also affects angiogenesis
“Fig. (2)”. A main effector molecule of the RAAS, Angiotensin II (Ang II), appears to
act as an angiogenic factor [76]. Thus, angiogenic effects of Ang II have been shown
in different models of angiogensis such as the chick chorioallentoic membrane [77],
sponge implants in rodents [78] and the rat cornea model [76]. Ang II induces
targeted migration of endothelial cells [79] and pericytes [80]. Endothelial cells
express high levels of both Ang II receptor subtypes, AT1 and AT2 [81]. Hence, Ang
II-induced migration via Ang II receptors appears to be a critical element for its
angiogenic effect. However, the exact mechanisms by which Ang II induces
angiogenesis are not fully elucidated yet.
The AT1 receptor mediates growth promoting effects of Ang II in endothelial cells,
while activation of the AT2 receptor leads to inhibition of endothelial cell
proliferation [81-85]. However, the AT2 receptor might also be important for
mediating angiogenesis [86] “Fig. (2)”. On the basis of the currently available studies
it is not yet possible to fully understand effects of angiogenesis mediated via the AT2
receptor [81-85]. This may be due to distinct model systems used to investigate the
role of the AT2 receptor [81-85]. There are other possible explanations for the
potentially conflicting effects mediated via the AT2 receptor, i.e., inhibition of
endothelial proliferation on the one hand [81-85] and induction of angiogenesis on the
other hand [86]; AT1 and AT2 receptors are sequentially expressed during
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microvascular maturation and therefore effects of endogenous Ang II on angiogenesis
may depend on the balance of their local expression [76, 87].
The RAAS is also involved in tumor angiogenesis. For example, renin can be
produced by both benign and malignant tumors [88-93]. In some of these tumors,
increased presence of renin is associated with the degree of vascularization [76]. Also,
some tumors express Ang II receptors [88, 93]. Thus, Ang II may hypothetically act
as a paracrine-autocrine factor that promotes tumor growth [76]. Inhibition of Ang II
should therefore theoretically repress tumor growth via repression of angiogenesis.
Indeed, different ACE inhibitors reduce angiogenesis in chemically-induced or
implanted tumors in rat - and mouse models [76, 79, 94, 95], partially due to
inhibition of proteases other than ACE [76, 79, 94, 95]. Interestingly, first clinical
observations have also suggested reduced rates of cancer in patients treated with ACE
inhibitors [96, 97].
At the same time and in contrast to tumors, ACE inhibitors may have angiogenic
effects in normal tissue [98, 99]. Angiogenic effects of ACE inhibition result probably
from Bradykinin (BK). ACE catalyzes the conversion of Ang I to Ang II and the
breakdown of BK to kinin degradation products. Therefore, pharmacological effects
of ACE inhibition on angiogenesis may in part be mediated via inhibition of Ang II or
also via accumulation of BK and subsequent BK-induced NO biosynthesis. Indeed,
several lines of evidence support a role of BK in modulating angiogenesis. BK
activates angiogenesis via FGF in endothelium from bovine coronary postcapillary
venules [100] and enhances angiogenesis in rat subcutaneos-sponge granuloma in
synergism with interleukin-1 [101].
BK acts via its two receptors, the BK1 and BK2 receptors. A substantial body of
evidence suggests that BK signal transduction for endothelium-dependent
vasodilation is mediated via the BK2 receptor [102]. The BK2 receptor is usually
expressed constitutively in various tissues [103]. However, myocardial ischemia can
trigger up-regulation of BK2 receptors in male Sprague Dawley rat hearts. [104]. The
angiogenic effect of ACE inhibition appears to be mainly mediated via BK and the
BK2 receptor [57, 58, 105]. Stimulation of the BK2 receptor induces activation of
eNOS and secretion of the angiogenic factor VEGF [57, 58, 105]. In BK2 knock out
mice, the capability of ACE inhibition to activate eNOS and induce angiogenesis is
abrogated [57]. This supports the concept that angiogenic effects of ACE inhibition
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are mediated via BK2-induced eNOS activation [57, 58, 105]. However, in addition to
the BK2 receptor, the BK1 receptor may also mediate angiogenesis. The BK1
receptor is undetectable under physiological conditions and strongly up-regulated
following tissue injury or inflammation [103]. For example, the BK1 receptor is
upregulated in ischemic skeletal muscle of mice [106] or ischemic myocardium of
rats [107]. In line with this observation, abrogation of BK1 receptor signaling inhibits
an angiogenic response in a murine model of hindlimb ischemia [108]. Conversely,
delivery of BK1 receptor agonist enhances collateral vascular growth in ischemic
skeletal muscle of mice [108]. In vitro, BK1 receptor activation stimulates endothelial
cell proliferation and survival [108]. Furthermore, BK acting via the BK1 receptor up-
regulates the angiogenic factor FGF-2 via the NOS pathway [59, 100]. Taken
together, BK seems to be a powerful angiogenic stimulus in vivo and in vitro “Fig.
(2)”.
Recent data also suggest a role for endogenous BK in tumor angiogenesis and tumor
growth [109, 110]. The angiogenic properties of endogenous BK in tumor growth
seem to be mediated by the BK2 receptor [109, 110]. In mice bearing sarcoma 180
cells daily administration of BK2 receptor antagonists suppresses the increment in
angiogenesis and tumor weight, whereas BK1 receptor antagonists do not affect
tumor growth [109, 110]. In these mice BK promotes angiogenesis by increasing
vascular permeability and by promoting up-regulation of VEGF [110].
Evidently, the data on ACE-inhibition and angiogenesis are not congruent. It is still
unclear why ACE inhibition might affect angiogenesis in divergent ways; in tumor
angiogenesis ACE inhibition appears to inhibit angiogenesis and to perhaps repress
cancer [76, 79, 94-97]. On the other hand ACE inhibition seems to lead to strong
angiogenic effects mediated via BK [57-59, 100, 105] and other effector molecules
such as FGF-2 [59, 100], eNOS [57, 58], VEGF receptors [58, 105], PKC [105] in
different cell types and in different models. These discrepancies may be due to the
presence or absence of different elements of the RAAS system in tumor tissue versus
non tumor tissue. Hypothetically, ACE-inhibition and subsequent reduction of Ang II
therefore overrides angiogenic effects of scarce BK accumulation in tumors. In non
tumor tissues Renin and Ang II may hypothetically be less involved in regulating
angiogenesis. Thus, accumulation of BK in response to ACE inhibition may be in the
foreground in these situations and result in angiogenesis “Fig. (2)”.
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Figure 2: Schematic representation of the Renin-Angiotensin-Aldosteron-System and
pathways that can affect angiogenesis.
Treatment of hypertension and improvement of angiogenesis (Table 1)
Antihypertensive therapy reduces cardiovascular events such as stroke and coronary
heart disease [111]. Main goals of the therapy are to improve morbidity, quality of
life, and mortality by inducing vasodilation, reducing vasoconstriction, and reverting
target organ damage. Some target organ damage caused by hypertension is related to
the microcirculation [111]. Therefore, antihypertensive therapy should also target the
microcirculation with, amongst others, the goal to reverse microvascular rarefaction.
Amongst the widely used classes of antihypertensive agents, ACE inhibitors and
potentially AT1 receptor blockers are the most promising to revert microvascular
rarefaction.
As extensively discussed in the previous section, ACE inhibition leads to
accumulation of BK which has a strong angiogenic potential mediated via both its
receptors. Accumulation of BK leads to endothelium-dependent vasodilation [102]
and a lowering of blood pressure. The beneficial effect of ACE inhibition on the
microvasculature is probably due to angiogenesis via BK and other molecules such as
FGF, VEGF, eNOS and PKC (see section above). In the following we illustrate the
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situation with a few examples of more clinically-oriented in vivo models; the ACE
inhibitor perindopril increases vessel density and capillary number in ischemic
hindlimbs of mice [57]. The BK2 receptor accompanied by an increase in eNOS
protein level mediates this increase of vessel density [57, 58]. Spirapril, another ACE
inhibtor, substantially increases myocardial capillary microvascular density in
spontaneously hypertensive rats [98, 99]. Spirapril also improves left ventricular
function by reducing its thickness and its hypertrophic weight [98, 99]. It is not
known whether improved function of the left ventricle is also due to enhanced
angiogenesis. Another ACE inhibitor, quinaprilat, promotes angiogenesis in a rabbit
model of hindlimb ischemia in vivo [98].
Much is known about Angiotensin II and its possible involvement in angiogenesis
(see section above). However, only little data is available on Angiotensin II receptor
blockers, which are commonly used to treat hypertension. Angiotensin II decreases
capillary density of the left ventricle in the long term [112]. AT1 receptor blockage
with candesartan in stroke prone spontaneously hypertensive rats increases left
ventricular capillary density and improves function of the left ventricle after the
animals were treated with Angiotensin II to induce cardiac hypertrophy [113].
Similarly, losartan prevents a decrease in the capillary density in the microvasculature
of the left ventricle of rats treated with Angiotensin II [112]. However, AT1 receptor
blockage with Losartan does not improve capillary density in stroke-prone
spontaneously hypertensive rats that were not treated with Angiotensin II [114].
These data suggest that AT1 receptor blockage is only able to revert capillary density
to normal if Angiotensin II was increased in the model [114].
Even less is known on other classical antihypertensive agents such as calcium
antagonists, a- and b-blockers, and diuretics. But recent data suggest that these agents
may also influence angiogenesis. The calcium antagonist verapamil induces
angiogenesis in the myocardium of rats with nitric oxide blockage [115]. Treatment
with several calcium antagonists (verapamil, nifedipine, and nimodipine) increases
vascular density on the chick chorioallantoic membrane [116]. In spontaneously
hypertensive rats, nifedipine expands the coronary capillary network [117].
Benidipine, a lon-acting calcium channel blocker, improves capillary density in the
left ventricle of hypertensive rats [118]. However, benidipine also suppresses
expression of angiogenic growth factors in a diabetic rat model [119]. In summary,
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calcium antagonists may reduce mircrovascular rarefaction, i.e., possibly improve
angiogenesis. However, this has not been extensively studied yet.
Virtually nothing is known about the effects of a- and b-blockers on angiogenesis,
although b-blockers are widely used antihypertensive agents. a1-Adrenoreceptor
blockers such as prazosin are known to increase capillary density in rat skeletal
muscle [120, 121]. Currently, third-generation b-blockers such as Nebivolol and
Carvedilol are more widely investigatd. These b-blockers have additional vasodilating
effects. Nebivolol for example, is a highly selective b1-adrenergic receptor antagonist
with additional b1-adrenergic independent vasodilating properties mediated by
increased NO biosyntheses [122]. It is unclear whether these regents can affect
angiogenesis.
Effects of diuretics on angiogenesis have barely been reported. Spironolactone, for
example, inhibits proliferation of smooth muscle cells [123] and also proliferation of
endothelial cells [124] in vitro. However, no effect of spironolactone is observed on
migration and rearrangement of endothelial cells into capillary-like structures in a
matrigel model in vitro [124].
First studies have examined the combination of different antihypertensive agents and
their effects on angiogenesis. Promising results were obtained by combination of
ACE inhibitors with diuretics [125, 126]. In stroke prone spontaneously hypertensive
rats a combination of a low dose of the ACE inhibitor perindopril and low doses of
the diuretic indapamide increases capillary density in the cardiac ventricles [125]. The
combination of both agents is more effective than administration of each agent alone
[125]. The same combination of perindopril and indapamide increases
neovascularization in ischemic hindlimbs of rats [126]. These results suggest that
combinations of different antihypertensive agents may be a promising possibility to
improve target organ damage because of hypertension and microvascular rarefaction.
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Table 1: Effects of Antihypertensive Drugs on Angiogenesis
Conclusion
There is little doubt about the evidence for abnormal angiogenesis in cardiovascular
disease, and increasing evidence points towards some role in the pathogenesis of
hypertension. Many of the currently available antihypertensive agents may have
beneficial effects on angiogenesis and thus potentially improve microvascular
rarefaction, corresponding target organ damage and function.
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Abstract
Neovascularization in the heart is usually investigated with models of angiogenesis in
vivo. Here we present a simple model that allows investigating heart angiogenesis in
mice and rats in vitro.
Small pieces of left ventricular myocardium were cultured in three-dimensional fibrin
gels for 10 days. A single mouse heart allowed assessing 24 conditions, each tested in
octuplicates. Rat recombinant VEGF164, human recombinant bFGF and human
recombinant PDGF-BB were used under normoxia (21% O2) and hypoxia (3% O2)
and outgrowth of endothelial sprouts from heart pieces was quantified. In 4-week-old
OF1 mice, endothelial sprouts formed spontaneously. In contrast, in 12-week-old
adult mice, virtually no sprouts formed under normoxia. Under hypoxia, sprout
formation increased substantially. Different growth factors induced formation of
distinct patterns of sprouts and unorganized single cells. Sprouts were composed of
endothelial cells with smooth muscle cells or pericytes interacting with them, as
assessed by inmunohistochemistry.
Taken together, our model is suited for investigation of angiogenesis of the heart in
vitro. It may allow performing extensive series of experiments in vitro including rapid
screening of pharmacological compounds and assessment of mechanisms of heart
angiogenesis in transgenic animals in an easy straightforward manner.
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Introduction
Ischemia of the left myocardial ventricle results from coronary heart disease or left
ventricular remodelling and microvascular rarefaction in hypertension. Angiogenesis,
serves to reduce tissue ischemia, i.e., hypoxia. Unfortunately, intrinsic angiogenesis
rarely fully compensates for the blood supply lost by occlusion of coronary arteries
[1]. A number of growth factors induce angiogenesis in vivo and in vitro and
stimulate endothelial migration or proliferation in vitro [2, 3]. Angiogenic growth
factors, such as VEGF164 (Vascular Endothelial Growth Factor) and bFGF (basic
Fibroblast Growth Factor) are released in response to hypoxia [4] and induce
angiogenesis in the heart [5]. Furthermore, expression of VEGF164 receptors flt-1 and
flk-1, and FGF receptor FGFR-1 increases in both acute [6] and chronic [7]
myocardial ischemia. Similarly, Platelet-derived Growth Factor (PDGF) limits the
extent of myocardial infarction via angiogenesis [8]. However, not much is known
about the mechanisms of PDGF-BB-mediated angiogenesis in the heart [8, 9].
Therapeutic angiogenesis aims at using angiogenic growth factors and other
therapeutic modalities to further enhance or promote new or collateral blood vessel
formation in order to reduce myocardial ischemia and thus improve myocardial
function [5, 10]. Recent first clinical trials with administration of different angiogenic
growth factors to the human heart have not been very successful [11, 12]. For this
reason, angiogenesis in the heart and possibilities to affect it need to be further
investigated.
Effects of angiogenic molecules on myocardial angiogenesis have been characterized
in a number of animal models in vivo [13-15]. These studies have demonstrated
enhanced collateralization in ischemic tissues, improved coronary blood flow,
improved functional capacity, and reduction in infarct size in response to growth
factors. Currently, most experiments are performed in vivo since no appropriate in
vitro model is available. In vivo experiments require large number of animals, are
difficult to perform and are often associated with pain to the animals. Many animals
die due to myocardial infarction and cardiac rhythm disturbances during sometimes
cumbersome surgical procedures. An appropriate in vitro model of angiogenesis of
the heart would resolve some of the problems encountered in vivo and potentially
reduce the number of in vivo animal experiments needed. Thus, the aim of this study
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was to investigate and validate a model of angiogenesis of the heart in vitro and to
assess the response of heart angiogenesis to known important angiogenic stimuli.
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Results
Basic conditions of the heart in vitro assay
First we established standard conditions for the in vitro heart angiogenesis assay using
small (0.5 to 1 mm3) pieces of left myocardial tissue of mouse or rat hearts embedded
in a fibrin gel. We investigated two cell culture media (Dulbecco’s minimal essential
medium, DMEM, and MCDB 131) (data not shown) with different concentrations of
foetal calf serum (FCS; 1, 2.5, 5 and 10% FCS; Fig. 1A) and evaluated the required
incubation period (Fig. 1B). DMEM proved to be the optimal medium (data not
shown) when supplemented with 5% FCS for our assay in both mouse and rat hearts.
This concentration is the maximal FCS concentration that shows no significant
growth in comparison to diluent and the one that shows the largest ratio between
stimulated and un-stimulated responses under hypoxic conditions.
Under hypoxia sprouts started to form 3 days after incubation and increased in
number up to day 10 of incubation (Fig. 1B). Virtually no in vitro angiogenesis was
observed under normoxic cell culture conditions (21% O2) (Fig. 1A and 4).
Fig. 1. Determination of standard conditions for heart angiogenesis in vitro in adult
mouse hearts.
(A) The serum concentration of the medium (DMEM) that covers the gel influences the
degree of sprout formation in response to human recombinant hrPDGF-BB (10 ng/ml) under
normoxia (21% O2) and hypoxia (3% O2). Sprouts were quantified with a standardized scale
ranging form 0 to 8 (angiogenic index). Medium containing 5% Fetal Calf Serum (FCS) was
found to be optimal because control sprouting (diluent) is low and sprouting can be amplified
by addition of hrPDGF-BB. (B) Spouting after 3, 5, 7 and 10 days in culture with addition of
5% FCS and 10 ng/ml hrPDGF-BB under hypoxia. Sprouting increases continuously up to 10
days of incubation. Data points represent the mean of a representative experiment ± SD (A
and B).
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Angiogenesis of the heart in vitro in comparison to a well-established assay of
aortic angiogenesis
To further characterize the assay of heart angiogenesis in vitro we compared it with a
well-established assay of angiogenesis in vitro that uses rat aortae [9, 16].
Angiogenesis in vitro in the heart was more restricted than in the aorta, indicating an
organ specific potential for angiogenesis. Under serum free conditions sprouts formed
from the rat aorta both under hypoxic or normoxic conditions, but the growth seen
under normoxia is negligible (Fig. 2) [9]. In contrast, there was no sprout formation
from adult rat hearts under normoxia or hypoxia in serum free culture (Fig. 2). With
serum-containing medium, both aorta and heart displayed similar degrees of cellular
outgrowth (Fig. 2).
Fig. 2. Angiogenesis in vitro of adult rat aorta versus adult rat heart is distinct in a
serum free culture.
In order to characterize the response in different organs, we compared growth in heart and
aorta of adult rats. This figure shows angiogenesis in vitro from pieces of rat aorta and heart
after addition of hrbFGF (10 ng/ml) or hrPDGF-BB (10 ng/ml) under normoxia (21%
oxygen) or hypoxia (3% oxygen) after 10 days of incubation in a fibrin gel without addition
of serum. On the right part sprout formation in rat hearts cultured in 5% FCS is shown as a
comparison. A standardized scale ranging from 0 to 8 indicates the degree of cellular
outgrowth (angiogenic index). No sprouting is observed under normoxia or hypoxia from rat
pieces of heart, but rat aorta sprouted under both conditions. Thus, angiogenesis in vitro in
aortae does not require the presence of serum in contrast to hearts. Data points represent the
mean of a representative experiment ± SD after 10 days of incubation.
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Age and angiogenesis
In an additional series of experiments we determined optimal age of animal hearts to
be used. We observed that the potential of the heart to form sprouts in vitro decreases
with the age of the animals (Fig. 3). Under hypoxia, hearts from 4 week old mice
(adolescent) displayed earlier and less restricted sprouting when compared to hearts
obtained from mice 12 weeks or older (adult). In adult mouse hearts, presence of FCS
in the medium was essential for sprout formation whereas adolescent mouse hearts
occasionally displayed weak growth even under serum free culture conditions (data
not shown). After 7 to 8 days of culture in a fibrin gel, sprout formation from
adolescent mouse hearts was already maximal. This degree of sprout formation was
only reached after 10 days in hearts of adult mice. As mentioned above, sprout
formation was much weaker under normoxia than under hypoxic conditions for both
ages tested. Thus, young mice exhibit a significant amount of growth even when un-
stimulated and achieve the levels of growth that older mice only reach when
stimulated. We conclude that the range of values is much smaller in younger than in
the older mice (12 weeks), making the latter the preferable choice for most questions.
Fig. 3. Sprouting in adolescent mice is less restricted than in adult mice.
Sprouting of heart pieces from adolescent (empty circles and squares) versus adult mice
(filled circles and squares) after 3, 5, 7 or 10 days of incubation in hypoxia under standard
culture conditions (DMEM 5% FCS) (circles) or after addition of hrPDGF-BB (10 ng/ml)
(squares). A standardized scale ranging from 0 to 8 indicates the degree of sprouting
(angiogenic index). Angiogenesis of the heart in vitro in adolescent mice occurs faster.
Adolescent mice display stronger sprouting at all measured time points (p < 0.05 Mann-
Whitney Test). Also, after addition of hrPDGF-BB growth is stronger and more extensive. At
day 10 adult mice hearts achieve similar levels of growth to those seen in adolescent mice.
Data points represent the mean of a representative experiment ± SD.
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Differential response to angiogenic stimuli
Hypoxia per se induced angiogenesis at a reduced level; all growth factors further
enhanced this response (Fig. 4). Specifically, human recombinant Platelet-derived
Growth Factor (PDGF-BB) strongly induced sprouting from mouse heart pieces
placed under hypoxia (Fig. 4). Compared to hypoxic diluent controls PDGF-BB
induced a 5.5 fold increase of sprouting. Under normoxic conditions PDGF-BB
induced sprout formation only weakly. In addition to PDGF-BB we also investigated
human recombinant basic Fibroblast Growth Factor (bFGF) and rat recombinant
Vascular Endothelial Growth Factor 164 (VEGF164) (Fig. 4). Compared to hypoxic
diluent control bFGF increased sprout formation 1.8 fold and VEGF164 2.3 fold.
Under normoxia neither bFGF nor VEGF164 induced sprout formation compared to
normoxic diluent control (Fig. 4).
Since repression of angiogenesis is of major scientific and clinical interest we also
used rapamycin as [9] an inhibitor of angiogenesis in our in vitro assay. PDGF-
induced sprout formation of hearts in vitro was repressed by application of
rapamycin, a specific inhibitor of mammalian target of rapamycin (mTOR) signalling.
This suggests that mTor may play a role in PDGF-induced angiogenesis of the heart.
(Fig. 4).
Fig. 4. Angiogenic growth factors induce reproducible sprouting in adult mice hearts
after 10 days of incubation.
Growth factors added to the culture medium containing 5% FCS under normoxia (21% O2) or
hypoxia (3% O2): hrPDGF-BB (10 ng/ml), hrbFGF (10 ng/ml), rrVEGF164 (5 ng/ml). Hypoxia
significantly increased sprouting in all experimental conditions in comparison to normoxia.
Sprouting was maximal in response to hrPDGF-BB under hypoxia (* = p < 0.05 Mann-
Whitney Test) but significant for all growth factors tested. A low dose (10 nM) of rapamycin
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effectively inhibits PDGF-BB-induced sprout formation. A standardized scale ranging from 0
to 8 indicates the degree of sprouting (angiogenic index). Data points represent the mean of
five independent experiments ± SEM.
Characterization of morphology
We then characterized outgrowing cells under hypoxic culture conditions in the
presence of 5% FCS by analyzing morphology and cell type. To typify single and
organized cells, we directly applied fluorescence labelled cell markers on the fibrin
gel cultures (Fig. 5). We used an Alexa Fluor labelled isolectin (GSL I –IB4) as an
endothelial cell marker, and Cy3 labelled anti a smooth muscle actin (aSMA) as a
marker for smooth muscle cells and pericytes. In pieces of heart cultured without
addition of growth factors some single cells migrated from the heart into the gel.
Occasionally, small branches formed spontaneously. A similar phenotype was
observed in cultures treated with bFGF (Fig. 5B and E). VEGF164 mainly induced
outgrowth of un-branched lengthy sprouts (Fig. 5C and F). In contrast, PDGF-BB
induced a mixture of all the observed phenotypes (Fig. 5A, D and G-I); a substantial
fraction of cells did not organize into sprouts. Still, many cells formed sprouts that
were more branched than those observed with VEGF164.
All tested growth factors induced organized sprouts of endothelial origin and
outgrowth of single cells of mixed origin as detected by cell specific stainings. Most
sprouts consisted of cells well organized into longitudinal tracts and branches
suggesting cord or tube formation. PDGF-BB induced outgrowth of the largest
number of endothelial cells (Fig. 5A). The fraction of non-endothelial cells was
proportional to the extent of total outgrowth, independent of the growth factor
applied. Some of the aSMA-expressing cells aligned along endothelial sprouts,
suggesting early stages of vessel maturation and capillary-like sprout formation (Fig.
5D-I).
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Fig. 5. Different growth factors induce sprouts with distinct morphologies under
hypoxia.
10 ng/ml hrPDGF-BB (A), 10 ng/ml hrbFGF (B) and 5 ng/ml rrVEGF164 (C) induce
substantial endothelial sprout formation as visualized by Fluorescein conjugated GSL I – IB4
(green). All growth factors induce growth of smooth muscle cells or pericytes as visualized
by Cy3 conjugated aSMA (red) ( D, H and I: hrPDGF-BB, E: hrbFGF and F: rrVEGF164).
Some smooth muscle cells or pericytes align themselves along endothelial sprouts (D, E, I
and arrows in F) suggesting vessel maturation.
We were able to isolate rat heart -but not mouse heart endothelial cells from the gels.
Subcultivation of outgrowing sprouts from rat hearts resulted in enriched endothelial
cell cultures, as assessed by endothelial cell markers. Over 90% of cultured rat heart
cells stained for endothelial cell markers CD31 and von Willebrand Factor (data not
shown).
To characterize sprouts ultrastructurally, we used confocal laser microscopy. Alexa
Fluor 448 conjugated GSL I – IB4 was used as a marker for endothelial cells, and
Cy3-conjugated lectin anti-smooth muscle actin was used as a marker for smooth
muscle cells and pericytes. A maximum intensity projection (Fig. 6A) of a bFGF-
stimulated explant demonstrates the close interaction between the endothelial sprout
and a smooth muscle cell or pericyte. The endothelial cells project filipodia into the
fibrin gel (arrows). Volume rendering of the same data set indicate that the sprout
appears solid, without a lumen (Fig. 6B).
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Fig. 6. Sprouting endothelial cells interact with smooth muscle cells or pericytes.
Heart pieces were stimulated with hrbFGF (10 ng/ml), and sprouts were stained after 10 days.
Smooth muscle cells or pericytes (red, probed with Cy3-conjugated anti-smooth muscle actin)
align themselves to endothelial sprouts (green, stained with Alexa Fluor 488 conjugated to
GSL I – IB4)  Deconvolved confocal image stack.
A. Maximum intensity projection. Arrows point to filopodia arising from the endothelial
cells. Scale bar: 20 mm
B. Volume rendering of the same data stack showing cell interactions. Note solid endothelial
sprout (green) lack a lumen and interact with apposed smooth muscle cells (red). Dimensions
of stack = 100 mm (x/y) and 10.5 mm (z).
68
To investigate myocardial tissue architecture and possible necrosis of heart tissue
after 10 days of hypoxia, pieces of hearts were histologically analyzed (Fig. 7). In one
of ten samples analyzed, necrosis could be detected in HE-stained tissue sections of
PDGF-BB-stimulated hearts. However, in nine of ten samples analyzed, myocardial
architecture was fairly well preserved, though cross-striations were faint and the
spatial distribution of myocardial nuclei had changed (Fig. 7).
Fig 7. Most pieces of heart preserve myocardial architecture after 10 days of culture.
HE-stained section of a piece of mouse heart after 10 days of PDGF-BB stimulation under
hypoxia in fibrin gels; myocardial architecture is fairly well preserved, though cross-striations
disappeared and the spatial distribution of myocardial nuclei begins to change. Cell
architecture resembles tissue as seen in ischemic myocard or after myocardial infarction (Bar
= 50 µm).
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Discussion
In this study we present a newly developed in vitro angiogenesis assay of the heart.
Pieces of rat or mouse hearts are cultured in a three-dimensional fibrin gel matrix and
outgrowing cells and sprouts are quantified and characterized. This in vitro model
may serve as a reproducible and reliable tool for analyzing induction as well as
repression of angiogenesis in the heart in vitro.
We found that hypoxia and serum are required for angiogenesis to occur in the adult
mouse or rat heart in vitro. FCS at a higher concentration (10%) to induced
angiogenesis by itself. Thus, we used the lowest possible FCS concentration (5%) to
avoid masking effects of growth factors by FCS. FCS contains numerous growth
factors which in combination can synergize to induce angiogenesis [17].
Under hypoxia, but not under normoxia, in vitro angiogenesis sporadically occurred
at a basal level in unstimulated heart cultures in the presence of 5% FCS. Under
hypoxia, but not under normoxia, PDGF-BB, bFGF and VEGF164 induced substantial
angiogenesis in vitro. Among tested growth factors, PDGF-BB most efficiently
stimulated in vitro angiogenesis. After 10 days of hypoxic culture, histology of
PDGB-BB stimulated hearts showed a fairly well preserved architecture of cardiac
tissue excluding possible necrosis. PDGF-BB-induced sprout formation could be
repressed by application of low concentrations 10nM of rapamycin. Rapamycin
specifically inhibits mTOR signalling and angiogenesis [9], [18]. mTOR has been
shown to up-regulate hypoxia-inducible factor 1-a (HIF-1a) [19] and increase
angiogenesis under hypoxia [9] and in tumors [20]. This effect of rapamycin in our
assay shows the possibility to investigate signalling involved in growth factor-
mediated heart angiogenesis and thus angiogenesis inhibitors in vitro.
Morphology of outgrowth differed upon administration of distinct growth factors.
VEGF164 mainly induced elongated sprouts with complex branching. PDGF-BB
induced outgrowth of a mixture of organized branched endothelial sprouts,
unorganized single endothelial cells and pericytes/smooth muscle cells, and bFGF
induced mainly un-branched and elongated sprouts. Independent of the growth factor
applied, sprouts were of endothelial origin. However, all growth factors also induced
substantial outgrowth of non-endothelial cells that correlated with the extent of
endothelial sprout formation. Thus, we have identified pure endothelial sprouts that
are distinct depending on the stimulus; smooth muscle cells or pericytes start to align
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along these sprouts, which is consistent with early vessel maturation. Similarly, in an
in vivo model of tumour angiogenesis, pericytes were shown to attach to endothelial
tubes at an early stage of sprout formation [21]. Nevertheless, it would be of great
interest to extend the culturing period further to investigate smooth muscle cell
pericytes attachment and thereby vessel maturation. However, our assay is time-
limited to 10-12 days. Gels of positive controls (PDGF-BB-stimulated hearts) reach
maximal and overgrowing sprout formation after 10 days of culture under hypoxia.
Also, gels start to degrade after 12 days and it is not possible to carry experiments
further.
Unlike later stages of angiogenesis in vivo continuous lumen is not present in the
sprouts at the time point studied (data not shown). This might be due to the absence of
blood flow and pressure in this assay of in vitro angiogenesis. Thus, physiologically
this model may correspond to morphogenesis at an early stage of angiogenesis.
Importantly, rat endothelial cells from the gels can be further subcultured. Cells
isolated were grown in medium enriched with endothelial cell supplement and, were
of endothelial origin in 90% (data not shown). Isolated cells were then utilized for
further experiments. Rat endothelial cells were kept in culture for maximally 14
passages. Unfortunately we were unable to subculture mouse heart cells for more than
2 passages.
Potent angiogenesis in response to PDGF-BB in the heart in vitro may surprise. Most
clinical trials to improve angiogenesis in the heart focus on VEGF164 and bFGF [1, 5,
22-26] and less on PDGF [8, 27]. However, a recent study has shown that PDGF
limits the extent of myocardial infarction in a rat model via angiogenesis, and PDGF
is angiogenic in rodents [8]. Other studies have also shown that PDGF is angiogenic
in vivo and in vitro [28-30]. However, not much is known about mechanisms of
PDGF-induced angiogenesis in the heart. PDGF may directly affect specific
phenotypes of endothelial cells such as microvascular endothelial cells [29]. It may
additionally induce expression of VEGF and other angiogenic growth factors with an
endothelial specificity in non-endothelial cells and thus indirectly stimulate
angiogenesis. In our assay we cannot exclude or confirm either of the two
possibilities.
Age reduces the potential for angiogenesis [31-38]. Correspondingly, angiogenesis in
vitro occurred earlier and was induced more easily in hearts of adolescent mice as
compared with adult hearts. In few experiments with 20 weeks old mice, angiogenesis
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was even more restricted than in the 12-week-old adult mice (data not shown). Age
dependency of angiogenesis is in line with studies in vivo [31, 32, 34, 35] and in vitro
[33, 36-38]. Angiogenesis allows normal tissue growth during development [39-42]
and is necessary for organs and animals to mature. Specific physiologic and many
pathologic processes reactivate angiogenesis [2, 39-41, 43]. However, the capacity for
reparative mechanisms and angiogenesis decreases with age [31-35]. Thus,
decreasing angiogenesis of the heart in vitro with age in our model is in line with
corresponding observations in vivo [31-35]. Our results indicate that angiogenesis is
restricted in the adult heart in vitro especially in comparison to other assays in vitro
but still inducible by specific stimuli such as hypoxia and growth factors.
We compared our heart angiogenesis in vitro model to an aortic ring explant model
which is a well-established and a widely used standard assay for angiogenesis in vitro
[9, 16, 44-46]. Angiogenesis in heart and aorta differed slightly. In vitro angiogenesis
of aortae also occurred under normoxia and in serum free culture conditions in
contrast to in vitro angiogenesis of hearts. This indicates that angiogenesis may be
regulated in an organ specific manner depending on culture and microenvironmental
conditions. Similarly, others have reported angiogenesis to be regulated in an organ
specific way and therefore claim a need for organ specific models [47, 48]. An
alternative explanation of the differential findings in aortic versus heart assays may be
that endothelial cells sprouting from a rodent aorta [9, 16, 44-46] are very likely of
macrovascular origin. In contrast, endothelial cells sprouting from a small piece of
heart are likely of microvascular origin, similar to angiogenesis in vivo [39].
Differences between the two assays may therefore also be due to micro- versus
macrovascular origin of the endothelial cells. This hypothesis would be further
confirmed by investigating the origin of sprouting cells in our in vitro assay.
However, the characterization of sprouting cells in our assay is currently limited to
the use of fluorochrome-conjugated antibodies and has to be further developed. The
more restricted pattern of angiogenesis in the heart suggests a strong need to assess
angiogenesis in a model that utilizes the organ of interest.
Experiments performed in rodents may not always be representative for humans.
However, preliminary experiments with small pieces of explanted human left
ventricle obtained from a heart transplant recipient displayed a similar angiogenic
response in vitro (data not shown). Similar to rodent hearts a combination of growth
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factors and hypoxia promoted sprout formation. Recently, a similar in vitro
angiogenesis assay using samples of human cardiac auricle has been developed [49].
Comparable to our results VEGF165 and FGF induced in vitro sprout formation by
endothelial cells. In contrast to our results in mouse hearts, sprouts formed without
addition of serum and under normoxic culture conditions. Differences between these
two assays might be due to culture conditions, the difference in species, the different
origin of the pieces from within the heart (left myocardium versus auricle), or other
distinctions. In summary, the majority of our data obtained in rodents are in line with
results obtained with human hearts [49]. Human tissue is not readily available and
very often from diseased heart or parts of the heart of lesser interest for the question
asked. Therefore, rodent hearts remain an alternative. Apart from availability,
transgenic mice can be used to answer mechanistic questions in heart angiogenesis in
vitro.
Obviously, our assay may not completely reflect myocardial angiogenesis in vivo.
However, organ culture models may better simulate in vivo situations than other
assays in vitro because they include surrounding non-endothelial cells in their
microvascular environment. In addition, endothelial cells have not been pre-selected
by passaging, are not in a proliferative state at the time of initiation of the experiment
and may thus better represent a real-life situation [50, 51]. Hence, sprout formation in
our assay could be mediated by direct stimulation of myocardial endothelial cells and
possibly also by stimulation of surrounding hypoxic myocardial tissue which then
acts on endothelial cells to promote angiogenesis. Endothelial sprouting in response to
angiogenic molecules therefore reflects the integrated interactions of different cell
types and the entire myocardial tissue and not the primary response of endothelial
cells alone. Thus, all our results have been very similar to in vivo situations (age,
growth factors), and we conclude that results obtained with our assay are likely to
represent other situations in vivo.
We have chosen a oxygen concentration of 21% O2 for normoxia and 3% O2 for
hypoxia. However, we do not know the exact oxygen concentration in the piece of
heart embedded in the culture gel. 21% and 3% O2 represent oxygen concentrations in
the incubator. Oxygen diffuses into the piece of heart and keeps most pieces viable
for 10 days (see above). The effective oxygen concentrations to which the pieces and
tissues of heart are exposed are lower in our experiments than the numbers given and
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are not yet defined. To further investigate hypoxic oxygen concentrations we also
investigated 1% O2 on PDGF-stimulated hearts (data not shown). However, there
were no differences in sprouting in response to PDGF-BB versus diluent between 1
and 3% O2 (data not shown).
In conclusion, angiogenesis of the heart in vitro can be investigated with a simple
assay. This assay allows a large series of experiments to be performed with a
minimum of animals in a relatively short time. We have demonstrated the reliability
of our model by reproducing known in vivo and in vitro phenomena. This model may
allow to evaluate mechanisms of angiogenesis in hearts of normal, diseased and
transgenic animals and to investigate substances that induce or repress angiogenesis
in the heart.
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Material and Methods
Animals
Experiments were performed with hearts and aortae of different mouse strains,
mostly with OF1 mice. In addition, a few key experiments were repeated in black six
mice to assess for potential inconsistencies amongst distinct mouse strains and in
Sprague Dawley rats for inconsistencies across species. All hearts and aortae were
obtained post mortem. The animals were euthanized and the hearts immediately
transferred to PBS. Within half an hour after death the mouse hearts were embedded
in fibrin gel (see below). To avoid damage to the heart tissue, hearts and aorta were
consistently covered with PBS (also during fragmentation into small pieces).  Mouse
hearts and aortae were obtained from Dr. Bastian Hengerer at Novartis Basel
(experiments registered and approved at the Veterinary Department of the city of
Basel, ID 1687, experiment ID 20108). Rat hearts and aortae were obtained from the
group of Prof. Peter Buser (experiments registered and approved at the Veterinary
Department of the city of Basel, ID 791) and from the group of Prof. Stephan
Krähenbühl (experiments registered and approved at the Veterinary Department of the
city of Basel, ID 1744). Ages ranged from 4 to 20 weeks for mice and from 6 to 20
weeks for rats.
Assay of angiogenesis in vitro
Preparation and evaluation of the assay are similar for heart and aorta. The assay is
based on the “three-dimensional” angiogenesis in vitro assay originally established by
Nicosia and colleagues [16]. Briefly, gels were made by preparing a fibrin gel
solution: 3 mg of Fibrinogen (Sigma-Aldrich, Buchs, Switzerland) per ml serum-free
DMEM (Oxoid, Basel, Switzerland) with 0.1U/ml of thrombin (Sigma-Aldrich,
Buchs, Switzerland) on ice. 100 µl/ well of this fibrin gel solution were immediately
pipetted into each well of 48-well plates and allowed to polymerize for 30 min at
37°C. Gels were overlaid with 500 ml serum-free DMEM for at least 30 minutes. The
medium overlaying the gel was removed and 0.5 - 1mm3 cubes from the left
ventricular myocardium of the heart or the aorta were placed onto the gels in each
well and overlaid with 100 ml of fibrin gel solution. After 30 minutes of
polymerization, gels were overlaid with 500 µl standard DMEM containing the
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indicated concentration of fetal calf serum (FCS, Oxoid, Basel, Switzerland). Heart
explants were then exposed to growth factors and incubated under normoxic (21%
O2) and hypoxic (3% O2) conditions for the number of days indicated, with addition
of fresh growth factors every second day: 10 ng/ml human recombinant (hr) PDGF-
BB, 10 ng/ml, hr bFGF, 5 ng/ml, hr VEGF164 (R&D systems, Minneapolis, MN); or
without addition of growth factors (diluent). Growth factor concentrations were based
on optimal doses for maximal proliferation in previously performed endothelial
proliferation assays using rodent rat endothelial cells (data not shown). Rapamycin
was added freshly 20 minutes before growth factors and included throughout
normoxic and hypoxic incubations. The effective concentration of rapamycin (Alexis
Corp (10 nM)) was established previously in mouse aortae [9]. Fibrin gels were
protected from degradation by adding 300 µg/ml e-amino-caproic acid (Sigma-
Aldrich, Buchs, Switzerland) every third day. After 10 days endothelial sprouts were
photographed digitally (ColorView II, Soft Imaging System, Gloor Instruments,
Uster, Switzerland) on an inverted light microscope (Olympus IX50, Olympus,
Schwerzenbach, Switzerland). The extent of sprout formation was determined for
each condition in octuplicates by comparison with a standardized scale (angiogenic
index) by two independent investigators and averaged.  The Angiogenic index was
defined with the help of an image analysis software (AnalySIS Pro, Soft Imaging
System, Gloor Instruments, Uster, Switzerland). The index is defined by the relation
between the total area of outgrowing cells to the area of the embedded tissue in study
(heart or aorta). Based on this a representative scale from 0 to 8 was defined.
Clear differentiations between agonists and antagonists can be seen after 7 days of
incubation. After more than 12 days gel cultures start to disintegrate. Therefore the
maximum incubation periods was set to 10 days.
Characterization of cells & tissue
For characterization of outgrowing cells and sprouts specific cell markers were
directly applied to heart cultures in the gels. The contents of the well were fixed over
night with 4% Paraformaldehyde (Merck AG, Dietikon, Switzerland), washed with
PBS and incubated for 3 hours with specific cell markers: Fluorescein conjugated
GSL I – IB4 (20 mg/ml; Rectolab S.A., Servion, Switzerland) for endothelial cells,
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Cy3-conjugated anti a smooth muscle actin (1:100; SMA; Fluka Chemie GmbH,
Buchs, Switzerland) for smooth muscle cells or pericytes and Hoechst dye
(Polysciences Europe GmbH, Eppelheim, Germany) for visualization of cell nuclei.
After incubation with cell markers the probes were extensively washed with PBS.
For histological sections fibrin gel containing heart piece were transferred into a tube
and fixed in 4% formalin overnight. Fixed tissue was embedded in paraffin and 2-4
µm sections were mounted, stained with haematoxylin-eosin (HE) and photographed
digitally (ColorView II, Soft Imaging System, Gloor Instruments, Uster, Switzerland)
on an inverted light microscope (Olympus IX50, Olympus, Schwerzenbach,
Switzerland).
Confocal Laser Scanning Microscope Observation
For characterization of outgrowing cells and sprouts, specific markers were directly
applied to heart cultures. Heart cultures were fixed overnight with 4%
paraformaldehyde (Merck AG, Dietikon, Switzerland), washed with PBS,
permeabilized with 0.2% Triton (Fluka Chemie AG, Buchs, Switzerland), washed
with PBS once more and incubated for 3 hours with specific cell markers: Alexa
Fluor 448 conjugated GSL I – IB4 (20 mg/ml; Molecular Probes, USA) for endothelial
cells, Cy3-conjugated antibody anti- a smooth muscle actin (1:100; SMA; Fluka
Chemie GmbH, Buchs, Switzerland) for smooth muscle cells and pericytes. After
incubation with cell markers the probes were extensively washed with PBS. Samples
were mounted in FluorSave Reagent (Calbiochem) on glass slides and examined by
confocal laser scanning microscopy using a confocal microscope (TCS 4D, Leica
Microsystems, Glattbrugg, Switzerland) operating in the simultaneous acquisition
mode. Image stacks were recorded using a planapochromatic 100x/NA 1.4 objective
lens.  Image stacks were recorded with a sampling density of 0.2 mm along the x- and
y-axes and of 0.1 mm along the z-axis.
Image processing and restoration was performed with the Imaris software package
(Bitplane AG, Zurich, Switzerland) equipped with the Huygens module (Scientific
Volume Imaging BV, Hilversum, NL). Deconvolution was performed as previously
described [52].
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Statistical analysis
All results depicted represent experiments repeated on at least five separate occasions
and using at least five different heart explants. Each single condition was performed
in octuplicate wells. Data points represent the mean of at least five single experiments
± SEM or the mean of a representative experiment ± SD. Statistical analysis was
performed where necessary with SPSS for Mac OS X (SPSS, Inc., Chicago, USA).
Statistical significance (p < 0.05) was established by using non-parametric analysis.
Kruskal-Wallis and Mann-Whitney tests were performed accordingly.
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iNOS is required for in vitro
angiogenesis of hypoxic healthy mouse
hearts
Veronica C. Munk, Rok Humar, Fabrice N. Kiefer, and
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Abstract
Nitric oxide (NO) is a key signaling molecule and regulator of angiogenesis.
Inducible NOS (iNOS) expression significantly increases during myocardial ischemia
and infarction, and iNOS modifies angiogenesis and vascular permeability but less
than eNOS as assessed in models of tumor angiogenesis. In this study we investigated
whether deficiency of iNOS affects myocardial angiogenesis under hypoxia in vitro.
Using three-dimensional-models of angiogenesis in vitro, we first investigated the
effect of pharmacological NOS (L-NIO) and specific iNOS inhibitors (1400WT and
SMT) on endothelial sprout formation of hearts and aortae from wild-type mice. In
aortae, only SMT markedly affected sprouting in response to PDGF (-29%, p < 0.05)
and VEGF (-52%, p < 0.04). However, in hearts all NOS inhibitors substantially
decreased sprout formation.
In hearts of iNOS (-/-) mice, when compared to hearts from wild type mice,
endothelial sprout formation did not occur at all under hypoxia and could not be
rescued with VEGF, FGF or PDGF. In contrast, endothelial sprout formation still
occurred, though to a reduced extent (-40% for diluent, -63% for PDGF, -61% for
FGF and –48% for VEGF, all p < 0.05), in pieces of aortae from the same iNOS (-/-)
mice when compared to aortae from wild type mice.
In conclusion, mouse heart vessels require iNOS for angiogenesis in vitro to occur
whereas angiogenesis in vitro originating from other blood vessel types such as the
aorta may depend less on iNOS.
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Introduction
Ischemia and tissue hypoxia of the myocardium occurs as a consequence of coronary
heart disease or left ventricular remodeling in hypertension. Ischemia elicits
vasodilation and angiogenesis, which serve to reduce tissue hypoxia.
Nitric oxide (NO) is an important signaling molecule that regulates physiological
processes such as neurotransmission, immune defense, cell death, vascular
permeability and vasodilatation in many tissues [1]. NO also modulates angiogenesis,
being required for endothelial cell proliferation and migration in vivo and in vitro [2,
3]. Thus, angiogenesis in vivo and growth-factor-mediated endothelial tube formation
in vitro require NO biosynthesis [3-8]. NO also enables growth regulatory molecules
such as VEGF and bFGF to induce angiogenesis [3, 9, 10]. We have previously
shown that Fibroblast Growth Factor (bFGF)-mediated angiogenesis requires NO in
the mesenteric vascular bed of normal and portal hypertensive rats in vivo [11, 12].
Some of these angiogenic growth regulatory molecules in turn can trigger NO-
synthases (NOS): VEGF increases permeability and decreases vascular tone by
activating endothelial NOS (eNOS) [13, 14]. Both inducible NOS (iNOS) and
(eNOS) (-/-) mice display impaired angiogenesis in a model of skin flap survival and
in the ischemic hindlimb, respectively [15-17]. eNOS plays a significant role during
reparative angiogenesis [18]. However, iNOS expression has been more extensively
described in tumor angiogenesis were it was found to be increased and its levels
correlated to vascularization [3-5]. To our knowledge, the role of iNOS on heart
angiogenesis has neither been studied in vivo nor in vitro so far. In this study we
therefore aimed at assessing the specific role of iNOS in angiogenesis of the heart in
vitro in comparison to another tissue under hypoxia. We have used a recently
developed in vitro model of angiogenesis in the heart [19] in comparison to a model
of angiogenesis in vitro from aortae and investigated endothelial sprout formation in
response to angiogenic growth regulatory molecules in wild type mice and in iNOS (-
/-) mice.
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Material and Methods
Animals
Experiments were performed with hearts and aortae of 8 to 12 week OF1 and iNOS (-
/-) mice (Strain: B6;129P2-Nos2tm1Lau/J, The Jackson Laboratory, Maine,-USA),
obtained and used immediately post mortem. Organs were received from Dr.
Christophe von Garnier at the Department of Research (University Hospital Basel)
(experiments registered and approved by the Veterinary Department of the city of
Basel).
Assays of angiogenesis in vitro
Pieces of heart [19] and aorta [20] were cultured inside a fibrin gel as described
previously. Explants were exposed to growth factors and incubated under moderate
hypoxia (3% O2) for 10 days, with addition of fresh growth factors every second day:
10 ng/ml human recombinant Platelet-derived Growth Factor-BB (PDGF-BB), 5
ng/ml rat recombinant Vascular Endothelial Growth Factor 164 (VEGF164) or 10
ng/ml human recombinant basic Fibroblast Growth Factor (bFGF) (all from R&D
systems, Minneapolis, MN). Endothelial sprouts were then photographed and
analyzed as described previously [19].
Inhibitors were included from initiation of the experiment and throughout hypoxic
incubation. 100mM of inhibitors were added freshly each time 20 minutes before
addition of growth factors. The following inhibitors were used: SMT (S-
Methylisothiourea), L-NIO (L-N5-(1-Iminoethyl)-ornithine) and 1400W (N-
(3(Aminomethyl)benzyl)acetamidine) (all from Alexis Corp., Lausen, Switzerland).
Statistical Analysis
All results depicted represent experiments repeated on at least three separate
occasions using different heart- and aortic explants. Each single condition was
performed in octuplicate wells. Data points represent the mean of all the experiments
± SEM. Statistical analysis was performed where necessary with SPSS for Mac OS X
(SPSS, Inc., Chicago, USA). Statistical significance (p < 0.05) was established by
using non-parametric analysis, i.e., Kruskal-Wallis and Mann-Whitney tests.
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Results
We have shown previously that angiogenesis in vitro of the heart of wild type mice
takes place only under hypoxia (1%-3% O2) and is amplified further by different
angiogenic growth regulatory molecules [19]. We have therefore performed all assays
of angiogenesis in vitro under conditions of moderate hypoxia (3% O2). To
investigate and compare whether results are specific for angiogenesis in the heart, we
also investigated in vitro angiogenesis in another tissue in parallel, namely aortic
explants from wild type and iNOS (-/-) mice.
To study the role of iNOS in angiogenesis of the heart we first included
pharmacological NOS inhibitors in assays of angiogenesis in vitro of wild-type hearts
and aortas. We focused on three NOS inhibitors; L-NIO, a general NOS inhibitor, and
two selective inhibitors of iNOS; SMT and 1400W. Under hypoxia the different NOS
inhibitors distinctly affected in vitro sprouting of aortae when compared to hearts
(Fig. 1).
In aortae, L-NIO and 1400W had very little effect on sprouting induced by PDGF and
VEGF, but SMT decreased sprouting induced by PDGF (- 29%, p < 0.05) and VEGF
(- 52%, p < 0.04) (Fig. 1A). In the heart, L-NIO and SMT significantly decreased the
levels of sprouting induced by PDGF (-35% and –51%, respectively, both p < 0.05)
(Fig. 1B). VEGF-induced angiogenesis in vitro was reduced by all NOS inhibitors; L-
NIO (-45%, p < 0.04), 1400W (-39%, p < 0.04) and SMT (-40%, p < 0.04) (Fig. 1B).
Thus, the effects of iNOS inhibition on angiogenesis in vitro were more pronounced
in mouse hearts than in mouse aortae.
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Figure 1. Pharmacological inhibitors of NOS reduce growth factor-induced in vitro
angiogenesis more in the heart (B) than in the aorta (A)
In vitro angiogenesis was quantified after 10 days in hypoxia and after addition of growth
regulatory molecules: PDGF-BB (10ng/ml) and VEGF164 (5ng/ml) combined with 100
mmol/L (mM) of pharmacological NOS inhibitors: 1400W, SMT and L-NIO. A standardized
scale ranging from 0 to 6 indicates the degree of sprouting (angiogenic index). Data points
given represent the mean of three experiments ± SEM. * = p < 0.05 (Mann-Whitney Test)
indicates significant difference to equivalent untreated controls.
To corroborate these findings, we studied the role of iNOS in heart angiogenesis in
vitro of wild type and iNOS (-/-) mice. In aortas of wild type animals PDGF-BB,
bFGF and VEGF induced angiogenesis in vitro (Fig. 2A). In aortas of iNOS (-/-)
animals sprout formation was clearly reduced in all conditions but still present (Fig.
2A). Endothelial sprout formation in aortas of iNOS (-/-) aortae was reduced by 40%
for diluent in comparison to in comparison to aortas of wild-type animals (p < 0.05),
48% for VEGF (p < 0.05), 61% for FGF (p < 0.05) and maximally by 63% for PDGF
(p < 0.05). In hearts of wild type mice, PDGF, bFGF, and VEGF induced substantial
angiogenesis in vitro as described before (Fig. 2B) [19]. In contrast, in vitro
angiogenesis of the heart in iNOS (-/-) mice was totally abrogated. None of the
growth factors tested induced any endothelial sprout formation (Fig. 2B).
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Figure 2. In vitro angiogenesis of the heart is abrogated under hypoxia in iNOS (-/-)
mice.
In vitro angiogenesis of aortae and hearts 10 days after addition of growth regulatory
molecules: PDGF-BB (10ng/ml), bFGF (10 ng/ml) and VEGF164 (5ng/ml). A standardized
scale ranging from 0 to 6 indicates the degree of sprouting (angiogenic index). Data points
given represent the mean of three experiments ± SEM. * = p < 0.05 (Mann-Whitney Test)
indicates significant difference to equivalent wild type samples.
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Discussion
In this study we have investigated whether iNOS is required for angiogenesis in vitro
of the heart versus aortae. In vitro angiogenesis of the heart in iNOS (-/-) mice under
hypoxia was totally abrogated and endothelial sprout formation could not be restored
with angiogenic growth factors VEGF, FGF or PDGF. We obtained similar results
with pharmacological NOS inhibitors. Most of the used NOS inhibitors, particularly
the iNOS-specific inhibitor SMT, substantially reduced but did not fully abrogate
sprouting in wild type hearts. The quantitative differences observed amongst the
different NOS inhibitors are probably due to their isoform specificity and their
particular mechanism of NOS inhibition. In Fig. 1B we observe that 1400W can
inhibit sprouting induced by VEGF but not by PDGF. This may suggest that PDGF
might activate pathways leading to endothelial sprout formation that are less
dependent on iNOS. PDGF-induced intracellular signals encompass a much broader
spectrum [21] than those in response to VEGF [22]. Furthermore, VEGF receptor
expression is restricted almost exclusively to vascular endothelial cells [23], while
PDGF receptors can be found in all connective tissue cells and certain other cell types
including endothelial cells [21, 24, 25]. Taken together our results in iNOS (-/-)
mouse hearts and with pharmacological NOS inhibitors suggest a central role for
iNOS in allowing angiogenesis of the heart.
Experiments in rabbits have shown that iNOS in cardiac tissue is expressed in
response to various physiological and pathogenic factors only. These include
myocardial infarction and inflammation [26]. Recent evidence, however, localizes
iNOS to neonatal and adult cardiomyocytes, to the myocardium of adult rats, and the
myocardium of patients with dilative cardiomyopathy [27].  Moreover, a
cardioprotective role of iNOS has been confirmed; iNOS   (-/-) mice are more
vulnerable to death after reperfusion and to myocardial injury associated with
myocardial ischemia and reperfusion injury than wild type mice [28]. Hypothetically,
decreased viability of iNOS (-/-) mice may also be due to impaired angiogenesis.
Angiogenesis is one mechanism that improves collateral circulation and thus blood
supply to ischemic areas. However, angiogenesis requires prolonged ischemia and a
few days to occur. Similar to the situation in vivo first sprout formation occurs after
~3 days in our in vitro assay, correlating with the time point of late cardiac
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preconditioning [29]. Our results support an important role for iNOS in heart
angiogenesis. iNOS may therefore protect from tissue ischemia via angiogenesis.
In addition, the requirement of iNOS in heart angiogenesis also suggests that
angiogenesis is regulated in an organ specific way. In vitro angiogenesis of the heart
was totally abrogated in iNOS (-/-) mice. In contrast, in vitro angiogenesis in aortas
was still present, albeit at a reduced rate and without a response to angiogenic growth
factors. This may be due to phenotypic differences of endothelial cells of large vessels
such as the aorta versus the cardiac microvasculature [30] from which endothelial
cells sprout to form new vessels. Thus, iNOS-independent pathways may exist that
can regulate angiogenesis in aortae and potentially many other organs and that are not
present or less active in the hypoxic heart. This supports the need of organ specific
models for angiogenesis [31] and the concept that the angiogenic response in adult
hypoxic hearts is far more restricted than in other organs.
Our experiments leave many questions unanswered. Effects of eNOS on angiogenesis
of the heart have not been investigated in this study and cannot be excluded. Other
experiments measuring myocardial capillary densities in eNOS knock out animals
have shown that deficiency in eNOS impairs myocardial angiogenesis [32]. The use
of NO donors to restore angiogenesis has not been examined. The role of iNOS on
angiogenesis of the heart in diseased hearts and in hearts of other species also remains
to be studied.
In conclusion, we have shown that in vitro angiogenesis of the heart under hypoxia
requires iNOS. Furthermore, we have shown an organ-specific requirement of the
heart for iNOS, i.e., that angiogenesis is more restricted in a model in vitro of the
adult hypoxic heart than in another model based on the aorta and that angiogenesis is
regulated in organ-specific ways.
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vitro through an AT2 – BKR2 pathway
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Abstract
Introduction: Arterial hypertension (AH) is characterized by increased
vasoconstriction through activation of the Renin-Angiotensin-Aldosterone System
(RAAS), but also by micro-vascular rarefaction in the heart, leading to myocardial
hypoxia. Hypoxia triggers angiogenesis that serves to relieve ischemia. Angiotensin II
(Ang II) has been reported to induce formation of new microvessels. This study aimed
to define the role of AT receptor subtypes in Ang II-mediated angiogenic effects of
the heart under hypoxia in vitro.
Results: Endothelial sprout formation from hearts of 12-14 week old wild-type B6
mice was assessed under normoxia (21% O2) and hypoxia (3% O2) during a 7-day
period of in vitro culture. Under hypoxia but not under normoxia, Ang II dose
dependently induced significant endothelial sprout formation. Maximal growth of
Ang II-treated hypoxic hearts was observed at 100 nM of Ang II (1.9 times of control,
p<0.05). AT1 blockade by Losartan did not affect Ang II-induced sprouting in the
heart of wild-type mice. Conversely, AT2 antagonist (PD 123319) abrogated this
response (-35%, p<0.05). In hearts from AT1 knockout mice, Ang II elicited
angiogenic response was preserved (1.9 times of control, p<0.05) and could also be
blocked by PD 123319 (-47%, p<0.05). In contrast, Ang II did not induce sprouting
from hearts of AT2 knockout mice. Interestingly, Ang II-mediated angiogenesis could
be abrogated with a specific Bradykinin receptor 2 (BKR2) inhibitor (HOE140) in
both wild type and AT1 knockout animals (-66% and –67% respectively p<0.05).
Finally, Ang II did not induce endothelial sprout formation in hearts from BKR2
knockout mice in contrast to wild type controls.
Conclusion: The results suggest a pro-angiogenic role of Ang Iiin the hypoxic heart
in vitro. The response to Ang II occurred only under hypoxia. Under these conditions,
Ang II induced angiogenesis via the AT2 receptor and interestingly the BKR2,
suggesting that the AT2 receptor activates the BKR2 via a yet unknown mechanism
to mediate angiogenesis.
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Introduction
Angiotensin II is a key regulator of blood pressure and a main effector peptide of the
Renin Angiotensin Alsoterone system (RAAS). The RAAS and its components are
targeted to treat hypertension in humans [1]. Hypertension can lead to left ventricular
hypertrophy and ischemic heart disease; these conditions are characterized by
insufficient blood supply to the myocardium. This leaves vital myocardial areas
ischemic and impairs myocardial function. Myocardial angiogenesis, i.e., the growth
of new microvessels, is one of the endogenous protective responses to counteract
tissue hypoxia.
Interestingly, Ang II tends to restore blood flow in the setting of acute ischemia in
mice [2]. This may be due to the activation of pre-existing collateral vascular
pathways. Moreover, Ang II is angiogenic in animal models of hind limb ischemia [2]
and the rabbit cornea angiogenesis assay [3]. However, it is unclear how and under
which conditions Ang II might act as an angiogenic molecule in the heart; At least
two distinct Ang II receptor subtypes (designated subtypes 1 and 2) have been
identified on the basis of their difference in structure and pharmacological and
biochemical properties [4, 5]. Both Ang II receptor subtypes, AT1 and AT2, are
expressed in the heart [6]. It is through the activation of the AT1 receptor, that Ang II
exerts many of its well established cardiovascular effects, including vasoconstriction,
sodium retention, aldosterone secretion and trophic effects [7]. The AT1 receptor is
expressed ubiquitously. By contrast, the physiological role of the AT2 receptor
remains to be fully defined. The AT2 receptor is constitutively expressed at low
densities in the adult in adrenal glands, vascular endothelial cells, kidneys, uterus,
ovarian granulosa cells and some brain areas [7]. AT2 receptor is upregulated in
cardiac tissue in response to ischemia and inflammation [8]. A number of different
experimental models, suggest that the mechanism underlying some AT2 receptor
functions may involve the release of endothelial-derived vasodilators, nitric oxide
(NO) and Bradykinin (BK) [9-11]. BK has been shown to promote angiogenesis via
its BKR2 by increasing vascular and endothelial permeability and by up-regulating of
VEGF via BKR2 [12]. Under some specific circumstances such as ischemia and
myocardial hypoxia, the AT2 receptor may thus counterbalance the vasoconstricting
effects of the AT1R.
In the present study we have investigated the angiogenic capacity of Ang II in an in
vitro model of angiogenesis of the rodent heart under conditions of normoxia (21%
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O2) and severe (1% O2) hypoxia. We aimed to better define the role of AT receptor
subtypes in Ang II-mediated angiogenic effects by using selective pharmacological
agonists and antagonists as well as knockout mice for the various receptors.
Furthermore, we have examined the involvement of Bradykinin receptor 2 as a
possible effector downstream of AT receptor activation.
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Results
Angiotensin II induces sprouting of the adult mouse heart under hypoxia.
We first tested the effect of Angiotensin II (Ang II) in an in vitro model of
angiogenesis in the heart both under normoxia (21% oxygen) and hypoxia (1%
oxygen). Under conditions of normoxia neither Ang II, nor the angiogenic growth
factor VEGF [13] that was used as positive control elicited a significant response (Fig
1a and 1b). Under hypoxia both VEGF and Ang II elicited a significant response
when compared to their normoxic controls (Fig 1a and 1b). Both these responses were
of similar magnitude (2,2 and 2,4 fold increase respectively, when compared to
negative control p<0.05) (Fig 1a and 1b). To characterize the cells involved in Ang II-
induced sprout formation, fluorescence-labelled cell markers were directly applied on
the fibrin gel cultures (Fig. 1a insert). These stainings showed sprouts of endothelial
cells and, aligned to them smooth muscle cells/pericytes.
Figure 1a: Heart Angiogenesis Assay.
Mice heart after 7 days in culture in 1% oxygen (a, b, c) or 21% oxygen (d, e, f). Stimulated
with 100nM angiotensin II (a,d); stimulated with 10ng/ml VEGF (b, e) or untreated (c, f).
Magnification: 40X. Insert:Endothelial cells are visualized by Fluorescein conjugated GSL I
– IB4 (green) and pericytes or smooth muscle cells by Cy3 conjugated aSMA (red), nuclei
were stained with Hoechst (blue).
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Figure 1b: Angiotensin II induces sprouting in adult mouse hearts in hypoxia.
Angiotensin II (100 nM) or VEGF164 (10 ng/ml) were  added to the culture medium
containing 5% FCS under hypoxia (1% oxygen) or normoxia (21%) for 7 days. Ang II and
VEGF induced sprouting to a similar extent.  Hypoxia significantly increased sprouting in all
experimental conditions in comparison to normoxia and in hypoxia Ang II and VEGF
induced significant sprouting with respect to control (*p<0.05 Mann-Whitney test). A
standardized scale raging from 0 to 4 indicates the degree of cellular outgrowth (angiogenic
index).  Data points represent the mean of 5 independent experiments + SEM.
Since hypoxia is a prerequisite for in vitro angiogenesis of the heart (see above and
[14]) we performed all consecutive experiments under hypoxia. To study the potency
of Ang II as an angiogenic factor we stimulated the pieces of hearts with a wide range
of concentrations of Ang II (100pM to 1mM). Only high concentrations of Ang II, i.e.
above 1nM to 1uM, induced angiogenesis under hypoxia (Figure 1c). Lower
concentrations of Ang II down to 1pM were also tested but did not induce a
significant angiogenic response (data not shown). Therefore we concluded that Ang II
dose dependently induces endothelial sprouting in the adult mouse heart under
hypoxia with a maximum at a concentration of 100nM.
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Figure 1c: Angiotensin II induces dose dependent sprouting in adult moue hearts in
hypoxia.
Angiotensin II (concentrations ranging from 1pM to 1uM) added to the culture medium
containing 5% FCS under hypoxia (1% oxygen) for 7 days. A standardized scale raging from
0 to 4 indicates the degree of cellular outgrowth (angiogenic index). Low doses of Ang II did
not induce significant sprouting but higher doses do, showing a clear dose dependency
(*p<0.05 Mann-Whitney test).  Data points represent the mean of 5 independent experiments
+ SEM.
Angiotensin II induces sprouting through the AT2 receptor.
Next, we determined, the AT receptor subtypes which are required for Ang II-induced
spout formation. The specific AT2 agonist CGP-42112 induced an angiogenic
response very similar to that observed when hearts were stimulated with Ang II (2
fold increase with 100nM CGP-42112) (Fig 2a).
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Figure 2a: The AT2 agonist, CGP-42112, induces dose dependent sprouting in adult
mouse hearts in hypoxia.
CGP-42112 (concentrations ranging from 1nM to 1mM) added to the culture medium
containing 5% FCS under hypoxia (1% oxygen) for 7 days. A standardized scale raging from
0 to 4 indicates the degree of cellular outgrowth (angiogenic index). CGP-42112 induced
significant sprouting at all concentrations tested in a dose dependent way (*p<0.05 Mann-
Whitney test). Data points represent the mean of 5 independent experiments + SEM.
CGP-42112 induced a dose dependent response with a peak at 10nM-100nM
suggesting that the AT2 receptor might mediate Ang II induced angiogenesis. To
further corroborate this finding pieces of hearts were stimulated with Ang II and with
pharmacological AT receptor inhibitors (Fig 2b). Losartan, an AT1 inhibitor, did not
have an effect on sprout formation induced by Ang II under hypoxia. On the other
hand, PD 123319, an AT2 antagonist, significantly reduced (-35%, p<0.05) the level
of sprouting induced by Ang II. When a combination of both antagonists was used the
response observed was very similar to that seen with PD 123319 alone (-40%).
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Figure 2b: Blockade with AT2 antagonist, PD 123319, abrogates Ang II-induced
sprouting but blockade with AT1 antagonist, Losartan, does not.
Angiotensin II (100nM) alone or in combination with Losartan (1mM) and/or PD 123319
(1mM) added to the culture medium containing 5% FCS under hypoxia (1% oxygen) for 7
days. A standardized scale raging from 0 to 4 indicates the degree of cellular outgrowth
(angiogenic index). Blockade with PD 123319 abrogates growth induced by Ang II (*p<0.05
Mann-Whitney test). Blockade with losartan did not induce a significant reduction in
outgrowth induced by Ang II (p=ns).  Data points represent the mean of 5 independent
experiments + SEM.
Also, CGP-42112-induced sprout formation could be inhibited by AT2 receptor
blocker (PD123319) but not by AT1 receptor blocker (Losartan)(data not shown).
Taken together, these results confirm the importance of AT2 receptor in mediating
angiogenesis of the adult mouse heart under hypoxia.
Angiotensin II does not induce sprouting in AT2 knockout animals.
In order to confirm these results we used hearts from different knockout animals.
Sprout formation was absent in hearts derived from adult AT2 knockout animals (Fig
3a) when stimulated with Ang II in hypoxia. The same results were obtained when the
AT1 receptor was blocked with Losartan. Stimulation of AT2 knockout hearts with
VEGF induced a significant level of sprouting when compared to controls (2.6 fold
increase, p<0.05) suggesting, that angiogenesis in vitro can still be induced via
mechanisms alterative to Ang II.
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Figure 3a: Angiotensin II does not induce sprouting in AT2 knockout mice in hypoxia.
Pieces of hearts from AT2 KO mice stimulated with angiotensin II (100nM) alone or in
combination with Losartan (1 mM) or VEGF164 (10 ng/ml) were added to the culture
medium containing 5% FCS under hypoxia (1% oxygen) for 7 days. A standardized scale
raging from 0 to 4 indicates the degree of cellular outgrowth (angiogenic index). Angiotensin
II could not induce a significant level of sprouting and blockade with Losartan did not change
this effect (*p=ns Mann-Whitney test), VEGF: *p<0.05 Mann-Whitney test. Data points
represent the mean of 5 independent experiments + SEM.
On the other hand, Ang II induced sprouting in hearts from adult AT1 knockout
animals (1.9 fold increase, p<0.05) under hypoxia (Fig 3b). This sprouting was
inhibited by PD 123319 (-47%, p<0.05), the inhibitor of the AT2 receptor, but not by
Losartan. Thus, the receptor mediating the angiogenic response in vitro to Ang II in
the heathy adult hypoxic mouse heart is the AT2 receptor.
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Figure 3b: Blockade with AT2 antagonist, PD 123319, abrogates Ang II-induced
sprouting in AT1 KO mice in hypoxia
To pieces of hearts from AT1 KO mice, angiotensin II (100nM) alone or in combination with
Losartan (1mM) and or PD 123319 (1mM)  added to the culture medium containing 5% FCS
under hypoxia (1% oxygen) for 7 days. A standardized scale raging from 0 to 4 indicates the
degree of cellular outgrowth (angiogenic index). Blockade with PD 123319 abrogates growth
induced by Ang II (*p<0.05 Mann-Whitney test).  Data points represent the mean of 5
independent experiments + SEM.
Angiotensin II induces sprouting via AT2 –BKR2 pathway
The AT2 receptor may interact with bradykinin receptor 2 (BKR2) as part of it’s
signalling pathway [15]. To study the role of the BKR2 in angiogenesis induced by
Ang II we stimulated hypoxic adult mouse hearts in vitro with Ang II in both wild-
type and AT1 knockout animals in the presence of HOE 140, a specific BKR2
antagonist (Fig 4a).
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Figure 4a: Blockade with BKR2 antagonist, HOE 140, abrogates Ang II-induced
sprouting in wild type and AT1 KO mice, in hypoxia.
Pieces of hearts from wild type or AT1 KO mice stimulated with angiotensin II (100nM)
alone or in combination with HOE 140 (100 nM)  added to the culture medium containing 5%
FCS under hypoxia (1% oxygen) for 7 days. A standardized scale raging from 0 to 4 indicates
the degree of cellular outgrowth (angiogenic index). Blockade with HOE 140 abrogates
growth induced by Ang II in both AT1 KO and wild type mice (§ p<0.05 Mann-Whitney test
or *p<0.05 Mann-Whitney test). Data points represent the mean of 5 independent
experiments + SEM.
In hearts from both wild type and AT1-KO animals, Ang II induced a clear
angiogenic response (wt: 3.5 fold increase, AT1-KO: 3.3 fold increase, p<0.05 for
both) that was abrogated by HOE 140 (-66% and –67% respectively, p<0.05). To
further corroborate the finding that Ang II-mediated angiogenesis requires BKR2
experiments were repeated in BKR2 knockout animals (Fig 4b). Neither Ang II nor
VEGF induced a significant level of sprouting in BKR2 knockout mice.
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Figure 4b: Angiotensin II does not induce sprouting in BK2 KO mice.
Pieces of hearts from BK2 KO mice stimulated with angiotensin II (100nM) alone or in
combination with PD123319 (1 uM) or VEGF164 (10 ng/ml) were added to the culture
medium containing 5% FCS under hypoxia (1% oxygen) for 7 days. A standardized scale
raging from 0 to 4 indicates the degree of cellular outgrowth (angiogenic index). Angiotensin
II could not induce a significant level of sprouting and blockade with PD 123319 did not
change this effect (*p=ns Mann-Whitney test). VEGF: *p<0.05 Mann-Whitney test.  Data
points represent the mean of 5 independent experiments + SEM.
We conclude that Ang II is angiogenic in the healthy adult mouse heart under hypoxia
and that this response is mediated via a pathway involving both theAT2 receptor and
the BKR2.
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Discussion
Our results demonstrate conclusively that Ang II induces angiogenesis in vitro of the
healthy mouse heart under hypoxia, but not under normoxia. This response is dose
dependent with a peak at 100 nM. Furthermore, the angiogenic response requires the
AT2 receptor and the BKR2 , but not the AT1 receptor. The data obtained are based
both on the usage of pharmacological agonists and antagonists of Ang II / BK
receptors and hearts of corresponding receptor knockout mice. Blockade of AT1
receptor preserves cardiac function after myocardial infarction by inhibiting AT1
receptor mediated pathways [16]. In addition, blockade of AT1 receptor pathways
may also uncover beneficial effects of Ang II via the AT2 receptor. The results of our
studies suggest that such beneficial effects may also be due to the stimulation of AT2
receptor culminating in angiogenesis.
The role of AT2 receptor in angiogenesis is not yet fully investigated. Microvessel
density was decreased after myocardial infarction in transgenic rats overexpressing
the AT1 receptor, and reverted by the use of Losartan [17]. Furthermore, Ang II-
induced angiogenesis observed in alginate implants is linked to the AT2 receptor;
impaired induction of angiogenesis was obtained in AT2 receptor knockout mice [18].
In our study Ang II and the AT2 agonist CGP-42112 induce angiogenesis of the heart
during hypoxia. This response was abrogated by HOE 140, a BKR2 inhibitor. In line
with this, Ang II was not able to induce angiogenesis in BK2 knockout mice. This
points at an important role of the BKR2 in angiogenesis mediated by Ang II. These
findings for the first time lend experimental support for the proposed mechanism, that
the AT2 receptor might exert downstream effects via the BK2 receptor [15].
Experimental evidence that BKR2 activation leads to angiogenesis, however, is
increasing. The proangiogenic effect of ACE inhibition is mediated by the BKR2
pathway [19]. Neovascularization was impaired in a model of hind limb ischemia in
BKR2 knockout animals as compared to wild type controls [19]. In consequence
vessel density and blood flow were impaired [19]. Other studies have shown that Ang
II can mediate renal production of BK, nitric oxide (NO) and cGMP via AT2 receptor
[9, 10, 20, 21]. Similarly, Ang II stimulates cGMP in stroke-prone hypertensive rats
by stimulating BK via the AT2 receptor [9]. A recent study suggests that AT2
receptors participate in BK-dependent vasodilation induced by Ang II [22].
Vasodilation of isolated rat arteries was maximally inhibited when both BKR2 and
AT2 receptor were blocked [22].
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Interestingly, vasodilation is a prerequisite for initiation of angiogenesis [23]. It is
therefore interesting that a vasoconstrictor molecule such as Ang II mediates its effect
via one of its receptors, i.e. AT2 receptor, through specific pathways, upregulated in
response to hypoxia, via a vasodilator molecule receptor, i.e. BKR2. Still, the precise
nature of the AT2-BK interaction has not been clarified to date. In endothelial cells,
Ang II reduces intracellular pH levels and this may activate acid-optimum
kinogenases that would cleave stored kininogens to produce BK and in turn NO [10,
11]. We therefore speculate, that BK-induced NO production via BKR2 may play a
role in AT2 mediated angiogenesis. Further characterization of the intracellular
pathways upregulated in response to hypoxia are needed to fully understand the roles
of hypoxia and the Ang II-BK interaction. The cells responsible for the observed
effects remain undefined since our system is a mixture of cell types, further
experiments using different cell types should be performed to answer more specific
questions since our method is not suitable for this. Our model dealt with healthy adult
mouse hearts in vitro, the role of Ang II on angiogenesis in vivo has not been studied
nor have we used hearts of diseased animals. These will be the topic of future studies.
In conclusion, Ang II induces angiogenesis in vitro in the healthy, adult, mouse heart
under hypoxia. The mechanism behind Ang II-induced angiogenesis requires the AT2
receptor as well as an interaction with the BKR2. Understanding the role and
interaction of these receptors in pathophysiological situations such as hypertension
and left ventricular hypertrophy, in vivo might lead to new insights for possible
treatments.
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Materials and Methods
Animals
Experiments were performed with hearts of different mouse strains: Black six wild
type mice, AT1 KO mice (The Jackson Laboratory, Maine USA: B6.129P2-
Agtr1tm1Unc) and BK2 KO mice (The Jackson Laboratory, Maine USA: B6;129S7-
Bdkrb2tm1Jfh). AT2 KO mice were obtained from Dr L. Hein as previously described
[24] All hearts were obtained post mortem. The animals were euthanized and the
hearts immediately transferred to PBS. Within half an hour after death small pieces
(1mm3) of the mouse myocardium (left ventricle) were embedded in fibrin gel. All
experiments conformed with the rules of the Swiss Federal Act on Animal Protection
(1998) and were approved by the Veterinary Department of the Kanton of Basel
Stadt(Switzerland). Age of mice ranged from 12 to 14 weeks.
Assay of angiogenesis in vitro
The assay utilized was a three-dimensional angiogenesis in vitro assay of the heart
established in our laboratory [14]. Briefly, gels were made by preparing a fibrin gel
solution: 3 mg of Fibrinogen (Sigma-Aldrich, Buchs, Switzerland) per ml serum-free
DMEM (Oxoid, Basel, Switzerland) with 0.1U/ml of thrombin (Sigma-Aldrich,
Buchs, Switzerland) on ice. 100 µl/ well of this fibrin gel solution were immediately
pipetted into each well of 48-well plates and allowed to polymerize for 45 min at
37°C. Gels were overlaid with 500 ml serum-free DMEM for at least 30 minutes. The
medium overlaying the gel was removed and 0.5 - 1mm3 cubes from the left
ventricular myocardium of the heart were placed onto the gels in each well and
overlaid with 100 ml of fibrin gel solution. After 45 minutes of polymerization, gels
were overlaid with 500 µl standard DMEM containing the indicated concentration of
fetal calf serum (FCS, Oxoid, Basel, Switzerland). Heart explants were then exposed
to stimulants and or inhibitors and incubated under normoxia (21% O2) and hypoxia
(3% O2) conditions for 7 days, with addition of stimulants/inhibitors every second
day: hr VEGF164 (R&D systems, Minneapolis, MN); HOE140 (D-Arg-[Hyp3,
thi5,D-tic,Oic8]-BK) (Sigma-Aldrich AG); Angiotensin II Human Acetate (Sigma-
Aldrich AG); Losartan Potassium 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-
ylphenyl)benzyl] imidazole-5-methanol-monopotassium salt (Merck Sharp & Dohme-
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Chibret AG, Glattbrugg, Switzerland), CCP42112 Nicotinoyl-Tyr-Lys(Z-Arg)-His-
Pro-Ile-OH (Bachem AG, Budendorf, Switzerland), PD123,319 Ditrifluoroacetate
(Fluka Chemie GmbH, Buchs, Switzerland).
Inhibitors were added freshly 20 minutes before stimulants and included throughout
the incubations where neceassry. Fibrin gels were protected from degradation by
adding 300 µg/ml e-amino-caproic acid (Sigma-Aldrich) every third day. After 7 days
endothelial sprouts were photographed digitally (ColorView II, Soft Imaging System,
Gloor Instruments, Uster, Switzerland) on an inverted light microscope (Olympus
IX50, Olympus, Schwerzenbach, Switzerland). The extent of sprout formation was
determined for each condition in octuplicates by comparison with a standardized scale
(angiogenic index) by two independent investigators , one of which was blinded to the
exact experimental conditions tested, and averaged.  In addition the angiogenic index
was defined, in selected experiments, with the help of an image analysis software
(AnalySIS Pro, Soft Imaging System, Gloor Instruments, Uster, Switzerland). The
index is defined by the relation between the total area of outgrowing cells to the area
of the embedded heart tissue. Based on this a representative scale from 0 to 4 was
defined.
Characterization of cells & tissue
For characterization of outgrowing cells and sprouts specific cell markers were
directly applied to heart cultures in the gels: The contents of the well were fixed over
night with 4% Paraformaldehyde (Merck AG, Dietikon, Switzerland), washed with
PBS and incubated for 3 hours with specific cell markers: Fluorescein conjugated
GSL I – IB4 (20 mg/ml; Rectolab S.A., Servion, Switzerland) for endothelial cells,
Cy3-conjugated anti-a-smooth muscle actin (1:100; SMA; Fluka Chemie GmbH,
Buchs, Switzerland) for smooth muscle cells or pericytes and Hoechst dye
(Polysciences Europe GmbH, Eppelheim, Germany) for visualization of cell nuclei.
After incubation with cell markers the probes were extensively washed with PBS.
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Statistical analysis
All results depicted represent experiments repeated on at least five separate occasions
and using at least five different heart explants. Each single condition was performed
in octuplicate wells. Data points represent the mean of at least five single experiments
± SEM. Statistical analysis was performed where necessary with SPSS for Mac OS X
(SPSS, Inc., Chicago, USA). Statistical significance (p < 0.05) was established by
using non-parametric analysis; Kruskal-Wallis and Mann-Whitney tests were
performed accordingly.
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4. CONCLUSIONS AND KEY FINDINGS
The aim of this study was to investigate the role of Angiotensin II and Nitric Oxide on
angiogenesis in the heart in vitro, independent of blood pressure using our newly
developed system. We also aimed to understand the mechanisms involved in these
responses. Both Ang II and NO are crucial in regulating blood pressure and involved
in many cardiovascular pathologies.
Hypertension is a mayor risk factor for many diseases, untreated it can lead to
arteriosclerosis, coronary heart disease, stroke, loss of vision and kidney failure,
among others. Most population-based studies confirm that hypertension increases an
individual's risk of cardiovascular consequences approximately two to three times [1].
Coronary Heart Disease is the leading cause of death worldwide. More than 60% of
the global burden of coronary heart disease occurs in the western world. In middle-
income countries cardiovascular disease is responsible for 18% of the disability-
adjusted life years (DALYs) lost, or the ‘healthy years of life lost’. [2].
While genetic factors play an important part, 80 to 90% of the people dying from
coronary heart disease have one or more mayor risk factors that are influenced by
lifestyle. The main risk factors associated with coronary heart disease are high blood
pressure, tobacco use, high cholesterol, alcohol consumption and obesity.
Stroke is also a mayor killer, annually 15 million people worldwide suffer from a
stroke, of these 5 million die and 5 million are left permanently disabled, placing a
burden of family and communities.  The mayor risk factors for stroke are similar to
those of coronary heart disease, with high blood pressure and smoking being the most
significant modifiable risks. Treating hypertension can reduce the risk of a stroke by
up to 40% [2].
Table 1 summarizes some basic facts and figures from around the world concerning
heart disease, stroke and the response of the local scientific community. The
economic losses that occur due to these two conditions are enormous, both to
families, businesses and communities, even without including the incalculable value
of a human life. The scientific community has responded to this challenge with a huge
amount of research being produced on these topics. In 2004 alone the number of
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published clinical trials in the National Library of Medicine (Pub Med) for coronary
heart disease is 57 507, an astonishing number when compared to the 6539 trials
published in the same period for HIV/AIDS.
Country Population
Thousands
Heart Disease Stroke Smoking
Prevalence
Research
1991-2001
DALYs
lost per
1000
Mortality DALYs
lost per
1000
Mortality
Argentina 37981 6 34292 6 22668 25% 110
South
Africa
44759 9 27013 11 30306 29% 77
Switzerland 7171 4 10746 2 4508 33% 440
USA 291038 8 514450 4 163768 25% 12502
Table 1: World Data Table obtained form the Atlas of Heart Disease ad Stroke
published by the WHO [2].
Given the importance of understanding the heart and hypertension and the importance
of improving blood circulation, our work has focused on the topic of vascular biology
and angiogenesis.
4.1 Hypertension and Angiogenesis
In the review ‘Hypertension and Angiogenesis’ published in 2003 in the Current
Pharmaceutical Design journal we attempted to discuss some basic mechanisms of
angiogenesis and their involvement in hypertension.
We also describe, the proposed pathways and actions of the main actors in the RAAS
suggesting that accumulation of BK in response to ACE inhibition may be responsible
for the resulting angiogenesis.
As a final conclusion we comment on the existence of evidence of abnormal
angiogenesis in cardiovascular disease and increasing evidence that it has a role in the
pathogenesis of hypertension. Since many of the available antihypertensive agents
have beneficial effects on angiogenesis they may improve the condition of
microvascular rarefaction and thus prevent organ damage.
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4.2 A versatile in vitro assay for investigating angiogenesis of the heart
In 2004 we published a paper in Experimental Cell Research entitled ‘A versatile in
vitro assay for investigating angiogenesis of the heart’. In this paper we describe a
new method for investigating angiogenesis [3].
At the time most experiments were being performed in vivo since no appropriate in
vitro model was available. In vivo experiments require a large number of animals, are
difficult to perform and are often associated with pain to the animals. A new in vitro
model would be desirable to solve some of these problems. Therefore, we aimed to
investigate, set up and validate a model of in vitro angiogenesis of the heart and to
then use this model to asses the angiogenic response of the heart to known angiogenic
stimuli.
In our study [3] we found that both hypoxia and serum (5%) are required for
angiogenesis to occur in the adult mouse heart in vitro. During hypoxia angiogenesis
occurred already at basal levels without addition of growth factors. Addition of
growth factors induced substantial levels of angiogenesis in hypoxia.  We
histologically analyzed the heart pieces after 10 days of hypoxic culture and found a
fairly well preserved architecture of the cardiac tissue and no necrosis. To investigate
the possibility of using this method to test inhibitors of angiogenesis we used
rapamycin. Inhibition was easily measured; this new model appears appropriate for
testing large numbers of compounds to find out if they might be pro-or anti-
angiogenic in the heart. To further describe this assay we analyzed the morphology of
the different sprouts. Not every substance tested induced the same type of branching.
However, sprouts were always composed by endothelial cells. Smooth muscle cells or
pericytes aligned along the sprouts, which is consistent with a stage of early vessel
maturation. A lumen was not present, also implying that this model may correspond
to an early stage of angiogenesis. Angiogenic potential is reduced with age and we
found the same to be true in our model. The older the mice, the less angiogenesis was
observed in the heart explants prepared from it. Our system was also tested with a
piece of human heart and results were similar to those obtained with rodent hearts.
We conclude that angiogenesis of the heart in vitro can be investigated with a simple
assay that allows a large series of experiments to be carried out in a relatively short
time and with a minimum amount of animals. We demonstrated the reliability of our
model by reproducing known in vivo and in vitro phenomena and we have seen that
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our model is suitable to investigate the actions of different substances on angiogenesis
of the heart. An important finding was that the model is suitable for studying both
substances that induce angiogenesis as well as substances that inhibit it.
4.3 iNOS is required for in vitro angiogenesis of hypoxic healthy mouse hearts
We have recently submitted a paper entitled ‘iNOS is required for in vitro
angiogenesis of hypoxic healthy mouse hearts’.
In this brief report we have investigated the role of iNOS on angiogenesis of the
mouse heart and aortae under hypoxia. We first used pharmacological inhibitors,
either general NOS inhibitors or specific iNOS inhibitors. We found that the heart is
more sensitive to the different inhibitors than aortae. When we repeated experiments
using iNOS knock out animals we obtained very clear results. We found that in
aortae, growth was reduced when stimulating with various growth factors. However,
in vitro angiogenesis of the hypoxic heart in iNOS knock out mice, was totally absent.
None of the growth factors tested was able to induce any sprout formation.
We therefore conclude, that organ specific pathways must exist for angiogenesis; and
that iNOS is essential for angiogenesis of the hypoxic mouse heart.
4.4 Angiotensin II induces angiogenesis in vitro through an AT2 – BKR2
pathway in the hypoxic mouse heart
The last of my research is described in ‘Angiotensin II induces angiogenesis in vitro
through an AT2 – BKR2 pathway in the hypoxic mouse heart’ a paper we are about to
submit pending approval by Merck Sharp and Dohme-Chibret AG.
In this paper we studied the role of Ang II on angiogenesis of the mouse heart in
hypoxia. We aimed to unravel the role of the AT receptor subtypes in angiogenesis
induced by Ang II and to study downstream effectors that might be involved in this
response.
We first tested the angiogenic capacity of Ang II and found it to be angiogenic only
during hypoxia. We then used various pharmacological tools to unravel the receptors
involved. We found that the AT1 antagonist Loartan does not block sprouting but an
AT2 antagonist does. An AT2 agonist also induced similar levels of sprouting as Ang
II. The role of AT2 receptor in angiogenesis was corroborated by the use of knock out
animals. In AT1 knock out mice Ang II induced sprouting and this was abrogated by
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the use of an AT2 inhibitor. On the other hand, AT2 knock out mice did not induce an
angiogenic response when stimulated with Ang II. This allowed us to conclude that
AT2 receptor was the one responsible for angiogenesis in our mouse heart in vitro
model. Thereafter, we decided to look at downstream effectors.
Based on the literature [4] we decided that BKR2 might be involved. We used both
pharmacological tools as well as transgenic animals to study whether BK might be
involved in this response. We found that sprouting induced by Ang II in wild type
animals could be inhibited with a BKR2 antagonist. When we used the BKR2 knock
out mice we were not able to induce any sprouting with Ang II.
These results fit in with a model of interaction between Ang II and BK proposed by
Volpe et al that can be seen in figure 8.
We thus conclude that Ang II is angiogenic in an in vitro model of the adult mouse
heart during hypoxia and that this response occurs via AT2 receptor and that BKR2 is
also involved in this response.
Figure 8: Proposed interactions among the AT2 receptors, the bradykinin and nitric
oxide systems. ACE= angiotensin-converting-enzyme; cGMP= cyclic guanosin
monophospahte; eNOS= endothelial nitric oxide synthase; L-NMMA= NG-monomethyl-L-
arginine. Figure from M. Volpe and P de Paolis, 2000 [4]
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4.5 Final Conclusion
Our work has ranged from the design of a new angiogenesis in vitro model to using it
to study angiogenesis in healthy adult mouse hearts. Using this model we have
studied the roles of Ang II and NO on angiogenesis of the healthy mouse hearts under
hypoxia and achieved our objectives resulting in the following conclusions:
1 The in vitro model of the mouse heart is suitable for studying angiogenesis in adult
mouse hearts under hypoxia and normoxia.
2. Sprouts induced in the mouse heart under hypoxia, are composed by endothelial
cells with smooth muscle cells/pericytes aligned along the sprout.
3. PDGF, VEGF and FGF were able to induce sprouting in the adult mouse heart
under hypoxia.
4. iNOS is essential for angiogenesis of the adult mouse heart under hypoxia
5. Ang II is angiogenic in the adult mouse heart under hypoxia
6. AT2 receptor is responsible for the sprouting induced by Ang II
7. BKR2 is involved in the angiogenic response due to the action of Ang II on its AT2
receptor.
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5. OUTLOOK
During the process of writing a thesis one learns a considerable amount and realizes
all that could still be done and all the many questions that remain unanswered. I
would like to outline some of these ideas.
1a.
We have described and characterized a novel in vitro model of heart angiogenesis.
The model may have a lot of potential and could be used for various applications such
as:
• Screening of compounds that might be angiogenic, that could later be used in
therapeutic angiogenesis
• Screening of anti-angiogenic compounds that might be later used in cancer
therapy
• Study diseased hearts as well as normal ones, for example hearts with Left
Ventricular Hypertrophy, diabetes, etc.
1b.
Our assay also provides a good model to study cell interactions at the initiation of
angiogenesis. It could be further utilized to:
• Study the cells that are involved at different stages of sprouting
• Study expression of receptors of interest
2.
In our brief report on the role of iNOS questions still remain unanswered such as:
• What is the role of eNOS in angiogenesis of the heart?
• Can angiogenesis be re-established by donation of NO?
• Can angiogenesis be re-established by induction of iNOS?
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3.
In our paper on the role of Ang II on angiogenesis of the mouse heart in hypoxia also
questions remain unanswered such as:
• What are the expression levels of AT1 and AT2 receptors in the mouse heart
in the different conditions analyzed?
• What is the role of NO in the AT2 /BKR2 pathway?
• What signalling molecules are responsible for the angiogenic response in
response to Ang II and to BK?
A lot of additional questions remain still unanswered. A lot of work is still to be done,
but that’s the magic of science, the work is never finished and there are always more
things to discover and learn about. As Mahatma Gandhi said, “Live as if you were to
die tomorrow. Learn as if you were to live forever”
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6. ABBREVIATIONS
ACE angiotensin converting enzyme
Ang II angiotenisn II
BK bradykinin
BKR1 bradykinin receptor 1
BKR2 bradykinin receptor 2
cGMP 3’,5’-cyclic guanosine monophosphate
DAG diacylglycerol
DALYs disability-adjusted life years
EC endothelial cells
eNOS endothlial nitric oxide synthase
FGF fibroblast growth factor
GPCR G-protein-coupled receptors
GTP guanosine 5’-triphosphate
 HIF-1 hypoxia inducible factor 1
iNOS inducible nitric oxide synthase
IP3 inositol triphosphate
KKS kallikrein-kinin system
LVH left ventricular hypertrophy
nNOS neuronal nitric oxide synthase
NO nitric oxide
NOS nitric oxide synthases
PLC phospholipase C
PRCP prolycarboxypeptidase
RAAS renin angiotensin aldosterone system
SMC smooth muscle cells
VEGF vascular endothelial growth factor
VSMC vascular smooth muscle cells
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